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Abstract
3D printing has much to offer to the field of medicine. The evolution of 3D printing has
enabled the design and creation of components previously unrealized with traditional
manufacturing techniques, allowing us to explore and customize solutions, quickly and
creatively. In its application to medical implants, 3D printing allows us to consider
embedding new and multiple functionalities within single components via elegant designs
and allows us to work with new and existing materials in innovative ways.

PDMS is a common biocompatible material used in many implants including, cochlear
implants. It has also been used as a passive release delivery mechanism for
pharmaceutical drugs but has received little attention in the field of biofabrication. This
study explores the 3D printability of drug-loaded PDMS, and investigates its potential for
use in the creation of drug delivery systems within implantable devices.

As a material possibly suitable for 3D printing, PDMS was explored as both a naked ink,
and hybrid ink loaded with dexamethasone. It was rheologically assessed in order to
understand its behaviour throughout the printing process and assess its suitability as an
extrusion printable ink. The printing protocol was optimised to produce uniform rows or
struts. A method was developed to assess these struts and hence the effectiveness of the
print protocols themselves. These protocols were then utilized to create appropriately
dimensioned 3D structures with potential applicability to the creation of drug delivery
devices, and specifically, the PDMS housing of cochlear implant electrode arrays. Drug
release studies confirmed the capacity of 3D printed PDMS to sustainably deliver
inflammatory reducing drugs over the long term.
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1. Introduction
1.1. Hearing Loss
Hearing loss currently affects one in six Australians (Deloitte Access Economics, 2006).
This has both economic and personal implications that are magnified when that hearing
loss is present from birth. Around 1 in every 650 babies born each year will have a
significant and permanent hearing loss (Mehl & Thomson, 2002). Any level of hearing
loss can impact a person’s ability to communicate, socialise and work in a predominantly
hearing community, but for children born prelingually deaf, that “hearing loss (also)
directly impacts on literacy and learning, (and) education” (Deloitte Access Economics,
2006) hindering cognitive development. Amplification of sound can be provided by
hearing aids in cases of mild and moderate hearing loss, but for children and adults with
moderate-to-profound hearing loss, for whom hearing aids are inadequate, cochlear
implants are seen as efficacious (Kirkby-Strachan & Que-Hee, 2016). Cochlear implants
create a sense of hearing for those who have a sensorineural hearing loss.

A cochlear implant consists of an external processor that takes in sound and converts it
into an electrical signal, executing the role usually performed by the hair cells in the
cochlea. This signal is passed from an external processor to an internal receiver, and then
on to an electrode array, which is surgically inserted into the cochlea. The electrical signal
stimulates the auditory nerve, producing the sensation of hearing. Whilst there are only
22 electrodes on this array, performing the role typically executed by around 11,000 hair
cells, the signal produced is sufficient to replicate the human voice in a way that allows a
person to understand speech. It is however, limited in its ability to reproduce sounds
outside of the range of human voice as the processing of the signal is focused on voice
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reproduction. This renders the understanding of sounds such as music quite difficult for
many recipients. Often, patients suffering hearing loss do not have a complete loss of
natural hearing. They may have some residual hearing in the lower frequencies. If a
patient can retain this natural hearing, they can combine it with the electrical stimulation
provided by the cochlear implant, giving a broader range of access to more frequencies,
and may be able to enjoy a better overall hearing experience.

Figure 1. Diagram of components of a cochlear implant (Yue, Moulton, Cook, O'Leary, & Wallace, 2013)

Whilst success rates for the implantation surgery are very high, both immediate and
delayed loss of some or all of a recipient’s residual hearing can occur. It has been
suggested that these hearing losses may be due to mechanical impact during electrode
array insertion causing an immediate inflammatory tissue response (O'Leary et al., 2013)
and a foreign body response causing chronic inflammation (Yu, Tutwiler, & Spiller). This
inflammation can damage the remaining hair cells in the cochlea. Chronic inflammation
may also contribute to a reduction in efficacy of the electrode array as it becomes
encapsulated in a fibrous sheath, increasing the impedance of the implanted array of
electrodes. (Bas, Dinh, Garnham, Polak, & Van de Water, 2012). Attempts to address the
mechanical impact issue are being made with improved surgical techniques and electrode
design but have not been fully resolved to date. Whilst the remaining tissue responses
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may not be fully understood, reducing these responses with pharmaceuticals “is
considered a safe and fast approach to reduce the immune response” (Farhadi et al., 2013)
and is seen as “an effective strategy for preventing delayed hearing loss in patients after
implantation” (O'Leary et al., 2013).

1.2. Treatment of Inflammation
The treatment of many conditions, including localised inflammation, can be improved by
localised and targeted drug delivery. Devices that transport the medication to the required
site enable the delivery of smaller dosages with fewer side effects than systemically
delivered medication. Implantable drug delivery devices can be located specifically where
the drug is needed, designed to fit a specific part of the body, and tailored to deliver drugs
over an appropriate period of time. One such approved device is the Propel Sinus Stent,
shown below in Figure 2, offering localised controlled drug delivery directly to the sinus
tissue over a 30 day period, and designed to expand into the shape of the sinus cavity of
an individual patient and hold it open (Parikh et al., 2014). It then dissolves away or can
be removed at any time.

Figure 2. Propel Sinus Implant (Intersect, 2018)
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The elegance and simplicity of the design of this device demonstrates the power of design
to meet specific and unique patient requirements, delivering medication to a specific site
by conforming to the shape of its environment, performing the mechanical role of holding
the cavity open, whilst also controlling the amount of drug released and the time period
over which it is delivered.

1.3. The Cochlea
Inflammation within the cochlea is particularly difficult to treat with systemically
delivered pharmaceuticals. The cochlea does not allow for the ready absorption of drugs
into the perilymph fluid via the bloodstream due to the blood-cochlear barrier (Pai & Lee,
2013). It has a bony outer structure, as seen in Figure 3 (A) below. The concentration of
drugs required to be delivered systemically in order to infiltrate the entire cochlea in
sufficient quantities can have potentially serious side effects.

Localised delivery of drugs directly to the perilymph fluid within the cochlea is more
efficient and effective but still problematic. The spiraling internal shape of the cochlea,
seen below in Figure 3 (B) makes it difficult to treat. The spiral completes 2 ¾ turns over
a 30 mm distance. There is the round window at the base of the cochlea through which a
hole can be made and has been used for the administration drugs prior to implantation
surgery. A single dose can be administered at the commencement of implantation surgery
but the extensive lead time required for the drug diffusion through the perilymph fluid, in
the order of 2 hours, is an undesirable increase in operating time. This increased surgery
time cannot be reduced by an increase in drug concentration. (Lee et al., 2015).

An implantable device, extending throughout the structure of cochlea, offers targeted,
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localised and controlled sustained release of drugs throughout the cochlea. It can reach
around the turns within the cochlea, delivering the drugs to the whole internal structure.
Leaving the implant in-situ allows it to continue to deliver drugs over a long period of
time, unrestrained by operating times. A controlled and sustained drug release mechanism
is preferred to effectively treat the initial and ongoing inflammation.

A

B

Figure 3. (A) 3D image from CT data of the middle and inner ear, including the bony cochlea (Paulose,
2011) (B). Colour-enhanced scanning electron micrograph of the inside of a guinea pig inner ear
(Furness, 2013)

1.4. Polydimethylsiloxane (PDMS)
Implantable devices need to be made from biocompatible materials. Biocompatibility
includes surface and structural biocompatibility. Surface biocompatibility refers to the
chemical and biological interactions between the body and the surface of the device.
These interactions include toxicity and inflammatory responses. These interactions can
be mitigated by appropriate material selection. Structural biocompatibility refers to the
mechanical interaction between the device and the surrounding tissue. This includes
weight, shape and flexibility (Hassler, Boretius, & Stieglitz, 2011) .
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PDMS, CH3[Si(CH3)2O]nSi(CH3)3, is considered to be the most widely used polymer in
siloxane (“silicone”) elastomers (Owen, 2001) and probably one of the most widely used
synthetic polymers for biomedical applications today (Hassler et al., 2011). It is cured by
a cross-linking reaction that joins the monomeric units [SiO(CH3)2] together, as
demonstrated in Figure 4, preventing irreversible flow. It is generally acquired in 2 parts,
referred to as Part A (pre-cursor) and Part B (catalyst). Combining the 2 components
enables the cross-linking.

Figure 4 Example of crosslink reaction of PDMS in the presence of a platinum catalyst, the silicone
hydride bond Si–H is replaced with an additional Si–C bond.(Sturgess, Tuck, Ashcroft, & Wildman, 2017)

PDMS is currently utilised in many implantable devices, including Cochlear Pty. Ltd.’s
cochlear implant, due to its bio-stability and longevity. In the case of the cochlea, there
are specific structural requirements for size, flexibility, softness and shape and various
variations in design due to different patient requirements, shown below in Figure 4.
Cochlear has their own proprietary form of PDMS to suit these requirements. The
Cochlear PDMS performs the role of a fluid-tight carrier for the metal electrodes, required
to provide the electrical stimulation within the cochlea, and the wires attached to them. It
is expected to do this over a period of several decades, surviving the lifespan of recipients
who may have been implanted as infants. It provides a mechanically stable structure with
sufficient stiffness to enable the device to be inserted and maintain its position within the
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cochlea, and the softness to cause a minimum amount of damage. It is non-toxic and
results in minimal surface interactions. The electrode housing is currently manufactured
by a multi stage molding process. The Cochlear PDMS is a liquid in the initial processing
stages, where it is poured into molds. The electrodes and wires are embedded within the
structure, and further layers of liquid PDMS are applied. The outer surface of the
electrodes are left exposed to stimulate the auditory nerve. The Cochlear PDMS is
thermally cross-linked with the application of heat to become a solid elastomer. It is in
this form that the Cochlear PDMS housing becomes suitable as a biomedical implant.

Figure 5. Various Cochlear Pty. Ltd electrode array options (Cochlear Pty Ltd)

PDMS is also suggested as a potential candidate for drug delivery devices due to its
biocompatibility and lack of toxicity. In polyurethanes containing PDMS, bio stability
has been shown to be unaffected by the incorporation of therapeutic drugs (Simmons,
Padsalgikar, Ferris, & Poole-Warren, 2008). PDMS has also been shown to demonstrate
prolonged and sustained release of therapeutic drugs for up to almost 100 days (Weaver
et al., 2015). Being hydrophobic, PDMS is suited to the incorporation of hydrophobic
drugs. PDMS-based delivery devices are commonly loaded with hydrophobic drugs to
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achieve prolonged release profiles of (Fu & Kao, 2010).

1.5. Dexamethasone
Dexamethasone, C22H29FO5 (chemical structure presented in Figure 6), is a
glucocorticoid commonly used for anti-inflammatory properties, reducing foreign body
reactions (Wrzeszcz et al., 2014). Research has shown various forms of dexamethasone
(Dex) have a positive impact on inflammatory responses specifically within the cochlea
(Bas et al., 2012).

Figure 6. Chemical structure of dexamethasone.

Dex is hydrophobic, and can be incorporated into polymer matrices using a variety of
approaches. These may include the introduction of Dex into a hydrophobic matrix at a
molecular level. Alternatively, Dex may be incorporated into a polymer matrix, that is
hydrophobic or hydrophilic, in the form of micronised particles or drug loaded
microspheres. Dex has been shown to suffer no significant degradation when processed
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via a Hot Melt Extrusion process at temperatures of up to 185 ºC (Li et al., 2013). Various
derivatives of Dex have been shown to be diffusively released from silicone matrices after
physical incorporation into the silicone (Herrlich et al., 2012). Rates varied from 7.6%
(dexamethasone-21-acetate, DexA) to 43.1 % (dexamethasone-21-dihydrogen phosphate,
DexP) of the drug load after 30 days (Figure 7). These release studies were performed
specifically on ring shaped constructs. These studies also showed the ability to slow down
the DexP release with the addition of a silicone adaptive layer providing a physical
barrier. Drug release profiles of Dex from polydimethylsiloxanes have been shown to be
predictable (Nemati et al., 2014) allowing us to design a controlled release mechanism.
This makes the silicone and dexamethasone combination a potential material for use in a
sustained drug delivery device.

Figure 7. (A) Cumulative released amounts of DexA(dexamethasone-21-acetate) per ring. (B) Cumulative
released amounts of DexP(dexamethasone-21-dihydrogen phosphate) and DexPX per ring. (Herrlich et
al., 2012)
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1.6. Biofabrication
Implantable devices fabricated with PDMS are traditionally manufactured via a molding
process where the PDMS is poured into molds as a liquid, cured, and then released from
those molds. This limits the design of these devices to shapes and sizes of structures that
can be molded. 3D printing, with its ability to create a more extensive variety of
structures, and with very small scale features, is an alternative fabrication approach
worthy of consideration. It is part of the field of biofabrication.

Biofabrication can be defined as the automated generation of biologically functional
products with structural organization from living cells, bioactive molecules, biomaterials,
cell aggregates such as micro-tissues, or hybrid cell-material constructs, through
Bioprinting or Bioassembly and subsequent tissue maturation processes (Jürgen et al.,
2016) It requires the disciplines of engineering, biology and materials science. 3D
printing belongs to the additive manufacturing component of the engineering field. The
inks used by the 3D printing process are a part of materials science. Whilst these materials
may not always be biologically based, the resulting products created for human use
certainly have interactions with the human body that belong to the field of biology. These
biological interactions drive the requirements of the design. In order to utilize 3D printing
technologies, all of these components must not only be considered in isolation. Their
complex interactions must be given thorough and careful consideration. An integrated
design approach lends itself to such a scenario. This allows us to consider the
requirements of each specialty area, and the impacts they are likely to have on each other.
By doing this, a meaningful integrated design solution can be offered.
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1.6.1. 3D Printing
3D printing enables the biofabrication process by offering us the opportunity to create
complex devices which may not otherwise be able to be manufactured. 3D printing can
be used to create uniquely shaped 3D structures. These structures can vary in scale from
buildings down to microchips, depending on the printing technology used. 3D printing
creates these constructs with an internal scaffold. The ability to not only use this scaffold
to determine the external shape of the construct, but to also design and utilize this internal
scaffold for specific functionality is a critical strength of 3D printing. These internal
features can be utilised as pore structures which are unable to be created with traditional
manufacturing techniques. (Jonathan & Karim, 2016).

3D printing offers precise control over differing properties of the internal scaffold,
including shape, size and layout, affecting the overall porosity of the construct. These
properties can impact the mechanical properties of the component, such as softness and
rigidity, allowing them to be tailored for the requirements of specific parts of the body.

3D printing can create small devices but also complex ones. By starting with very fine
individual struts, many varied designs can be created around them. This allows for
variations within structure and the design of components around them.

The resolution of the printed construct is important for precision of control in delivering
function. The more layers, the finer the resolution and the more potential for detailed
control over embedded functionality. By starting with very fine individual struts, many
varied designs can be created around them. This fine structure enables the embedding of
additional features with the potential for multiple functionality to be incorporated into a
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single design.

3D printing allows components to be made from a broad choice of core materials, or inks,
including polymers, metals, ceramics, nylon, acrylics and food. It enables us to load our
inks with other materials, creating bio-inks with many possible uses. One such material
is pharmaceutical drugs. This allows the drugs to be embedded within the ink and thus
become a part of a component before it is created. It provides the mechanisms for direct
fabrication of drug loaded scaffolds without post processing to include those drugs.

1.6.2. 3D Extrusion Printing
There are many potential 3D printing technologies, each suited to different applications
due to the inks they are capable of printing with and the resolutions they are capable of
creating. Extrusion printing is one predominant form of 3D printing and often used in
biofabrication. It appears suited to printing PDMS. Extrusion printers, as shown in Figure
8 (A) below, perform 3D extrusion printing by pushing a printable ink through a syringe,
via air (pneumatic) or mechanical forces, onto a printing stage in lines in an X-Y
orientation. A single layer is formed and then successive layers are added, in the Z
direction, to form a 3 dimensional shape, as shown in Figure 8 (B), by lifting the printing
nozzle before beginning the next layer. The 3 dimensional shape is designed ahead of the
printing process in CAD software and sliced by further computer software into these
individual layers.
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B
Air Pressure In

Printing Stage
Extrusion Nozzle

Figure 8. (A) Schematic of a generic 3D extrusion printer. (B) Printing nozzle and printed scaffold

Extrusion printing requires inks to be of appropriate viscoelasticity to allow them to be
readily pushed through a printer nozzle and self-recover to retain their printed shape.
Extrusion printing of inks that are in a liquid form requires that they have an appropriate
mechanism to induce the ink to transform into a stable state such that it will not spread
on the substrate and lose its form. These inks will often require post processing to turn
into a completely solid state.

Once appropriate inks are identified, extrusion printing gives us the ability to create robust
scaffolds from a wide variety of materials. It offers a reasonable level of resolution with
strand widths of 200 – 1000 µm (Kyle, Jessop, Al-Sabah, & Whitaker, 2017). It requires
specific physical properties from the ink in terms of shear thinning to allow it to be
extruded, and either self-recovery or a quick sol-gel transition after extrusion to avoid
wetting or spreading on the substrate.
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1.6.3. 3D Printing of PDMS
One of the primary challenges of 3D printing of PDMS is the flow of PDMS after
extrusion and resulting loss of fidelity. In one study, this was addressed by printing into
a support bath that was subsequently removed. This solution was successful but had
limitations with lateral fusing of the filaments (Hinton, Hudson, Pusch, Lee, & Feinberg,
2016). Other studies have successfully added photoresist materials to the PDMS to
overcome issues of long curing times and low spatial resolution (Femmer, Kuehne, &
Wessling, 2014). The addition of any materials to the PDMS ink requires careful
consideration of effects on biocompatibility and mechanical properties when assessing
for an implantable device.

1.6.4. 3D Printing in drug delivery
3D printing is relatively new to the field of drug delivery. Research has shown various
3D printing technologies capable of producing drug delivery devices (Jonathan & Karim,
2016). In considering 3D extrusion printing specifically, it has been shown capable of
producing tablets and implants as drug delivery devices. These devices contain various
materials, usually polymers, combined with various drugs. These polymers include
hydroxypropyl methylcellulose (HPMC), poly(lactic-co-glycolic acid) (PLGA), and
Poly(vinyl alcohol) (PVA). The table below (Table 1) highlights some of the
combinations of drugs and polymers and the drug delivery device options explored to
date using extrusion-based printing technologies
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Table 1. 3D Extrusion Printed Drug Delivery Devices

3D Printer

Polymer Drug

Technology
Extrusion

Delivery

Reference

Type
HPMC

Hydrochlorothiazide Tablet

(Shaban A. Khaled,
Jonathan C. Burley,

Pravastatin

Morgan R. Alexander,
Jing Yang, & Clive J.

Atenolol

Roberts, 2015)
Ramipril
Aspirin
Extrusion

PLGA

Dexamethasone

Implant

(Rattanakit, Moulton,
Santiago,

PVA

Liawruangrath,

&

Wallace, 2012)
Extrusion

PVA

Acetaminophen

Tablet

(A. Goyanes et al.,
2015)

Extrusion

PVA

Fluorescein

Tablet

(A. Goyanes, Buanz,
Basit,

&

Gaisford,

2014)
Extrusion

PVA

Paracetamol

Tablet

(Alvaro

Goyanes,

Robles

Martinez,

Buanz,

Basit,

&

Gaisford, 2015)
Extrusion

PVA

Prednisolone

Tablet

(Skowyra, Pietrzak, &
Alhnan, 2015)

The first FDA approved 3D printed tablet, Spritam® (levetiracetam), was released in
2015. With its release to the market, it showed the commercial viability of a 3D printed
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drug delivery mechanism. The production of this pill takes advantage of the ability of 3D
printing technology to manufacture porous structures. This porosity makes it easily
dissolvable in the mouth. This design shows the ability of 3D printing to incorporate
desired functionality, such as dissolvability, into the design.

There is interesting research into multi-functional designs such as a polypill with different
chambers to separate drugs (S. A. Khaled, J. C. Burley, M. R. Alexander, J. Yang, & C.
J. Roberts, 2015). This design prevents interactions between the drugs. 3D printing
provides the technology to easily produce these designs. There are also investigations into
alternative and more complex shapes, such as a torus, that are difficult to produce using
more conventional manufacturing techniques (Wang, Goyanes, Gaisford, & Basit, 2016).
The figure below, (Figure 9), shows images of these tablets and shapes. These shapes
offer the opportunity to deliver unique drug release profiles due to differing surface areas
affecting drug delivery.
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Figure 9. i) A 3D printed multi active tablet containing 5 drugs with sustained release lower
compartments and immediate release dotted compartment on top (Khaled, Burley et al. 2015), ii)
uniquely 3d printable torus shaped pills containing paracetamol and aminosalicylic acid (Wang et al.,
2016) iii) The first FDA approved 3D printed pill for epilepsy, Spritam® (Aprecia Pharmaceuticals) ,
utilising porous constructs for dissolvability.

The unique ability of 3D printing to create structures with unique shapes, customisable
internal scaffolds, with varied layers and precision controlled complexity, can be readily
applied to the needs of drug delivery devices. Inks can be pre-loaded with drugs before a
component is created, as with molding, but with the added benefit of being able to
distribute loaded inks in specific locations within the scaffold. This preloading with drugs
can provide improved results over coating devices with drugs. Sandler et al (2014)
demonstrated this by incorporating the hydrophobic, anti-microbial drug, nitrofurantoin,
into the polymer, poly(L-Lactic Acid) prior to processing. Structures were then 3D printed
and showed an improvement in biofilm inhibition over drug-coated devices.

Pre-loading can also be tailored and modified, enabling the creation of differing
concentrations of drugs within inks for use within a single structure, delivered by a single
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printing process. Flexibility of spatial control of drug delivery can be gained by uniformly
distributing the drugs throughout components, or by concentrating drugs in specific areas
where a drug is required. Differing layers, porosities, shapes and infill percentages can
produce drug-loaded scaffolds with complex and release profiles, tailored to a specific
body part or an individual patient.

Research continues into more personalised medicine with investigations into 3D printing
of individualised doses, but drug delivery research appears focused on oral devices, i.e.
tablets. Implantable devices with localised delivery offer lower dosages with controllable
release profiles over extended periods of time (Jiang et al., 2017) and can reach parts of
the body that may be difficult to reach via oral pathways. There are implantable drug
delivery devices on the market such as Implanon®, a contraceptive device implanted
under the skin in the arm, that releases drugs over a 3 year period, and continuing research
into various mechanisms designed as drug delivery devices such as implantable infusion
pumps (Meng & Hoang, 2012), but none to date that are 3D printed.

1.6.5. Integrated Design of 3D printed drug delivery
The design of 3D printed implantable drug delivery device requires an integrated
approach. This allows us to consider the individual requirements of the areas of materials,
engineering and biology, and the resulting impacts of design decisions made on the
relationships between these areas. These interdependencies are complex and require
careful consideration. Not only are the requirements complex and overlapping, but the
design can impact on fabrication and implementation of the solution.

The ink formulation, consisting of a base material and drug, is the first point of
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consideration. In 3D printing, printability is a key requirement of ink formulation.
Polymers are commonly used as the base material but the most suitable one must also be
chosen for its ability to perform a specific role in the body – such as degrading over time
or remaining stable. The biodegradability of the polymer also affects drug delivery
profiles. Drug choice is determined by patient need for specific role and body part. The
drug must also be able to be incorporated with a polymer into an ink in terms of solubility
but that also retains its printability. Printer choice is determined by the ability to formulate
a suitable ink for the printer, utilising an existing or determined printing protocol, and
also by its ability to produce a structure of a suitable morphology for its specific
application in the human body. The design of the drug-delivery device itself, including
surface profile and porosity, and the recipe of the ink formulation, all have significant
impact on the drug release profile. Regulatory approval must also be sought for the
specific drugs, polymers, and the final device itself. These properties can also impact drug
delivery both spatially and temporally. These interdependencies, as shown below in
Figure 10, must be resolved by the 3D design and fabrication process.
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Figure 10. Interdependencies of the biofabrication process

Innovative biofabrication techniques have the ability to bring a level of precision, control
and customisation that is unavailable using existing manufacturing techniques. These
techniques can be applied to not only new designs, but also existing designs, enabling the
creation of new function within these devices. These functions can include drug delivery
enabling drug delivery mechanisms to be created within new devices and also
incorporated into existing devices.

While the overall architecture of the printed structure influences its functionality, it is the
individual struts that impact what structures can actually be created. The width of the
struts influences the overall width of the 3D construct. The height and strength of each
layer impacts the number of layers that can be produced. The combination of these
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determines the overall shapes and sizes of constructs that are possible. The rheology of
the ink and the optimisation of the printing protocols, impacts on the producible struts
and it is to this that we focus our attention. The many interdependencies between
parameters within the print protocol make it difficult to isolate each parameter, as a
change in one necessitates a change in others to produce uniform struts.

As can be seen, there is complex overlap of the requirements of the design, fabrication
and implementation of an implantable drug delivery device. There are also complex
interdependencies within each area which must be resolved.

For applicability to the cochlea, the design requirements are initially anatomical in that
these devices must fit within the cochlea and so be small and have a specific shape.
Stiffness in the vertical plane should be higher than in the horizontal plane to avoid severe
insertion trauma to the cochlea (Stephen J. Rebscher et al., 2008). For drug delivery, shape
and its internal structure must also account for volume to surface area ratios that can
directly influence the release profile of individual drugs (Alvaro Goyanes et al., 2015).
Constructs of different layers, shapes, and porosity can have significant impact on drug
release profiles.

1.6.6. Clinical Application Design
The Cochlear implant is very effective in restoring hearing, but its efficacy could be
improved if inflammatory responses within the body were reduced. The need to reduce
inflammation caused by a cochlear implant can be addressed with an implanted device
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tasked with delivering anti-inflammatory drugs, but there is little room within the
confined space of the cochlea to insert an additional device.

The electrode array of the cochlear implant itself is designed to be safely inserted into the
cochlea utilizing a clever pre-curved and tapered shape with a temporary straightening
stent that permits it to be inserted as a straight structure and curls into the cochlea as the
stent is removed, limiting damaging mechanical forces on the cochlea shell. Giving the
cochlear electrode array the dual purpose of housing the platinum electrodes and
delivering drugs, elegantly resolves the issue of delivering drugs via a separate
mechanism and introduces the option to tailor the drug delivery profile. The diagram
below (Figure 11) shows a conceptual representation of the drug distributed throughout
the existing silicone housing, demonstrating where the drug delivery functionality could
be performed. The current design could be modified to incorporate this drug delivery
functionality in addition to the current functionality of insertion and indefinitely holding
the electrodes in place while maintaining bio stability. The drug delivery design can be
then tailored to deliver specific doses of drugs, to specific locations within the cochlea, at
specific times and rates. The process is required to create the drug embedded housing of
the cochlear implant, and to assess the release of those drugs requires evaluation.
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Figure 11. (A) A Cochlear electrode array with silicone housing around platinum electrodes (Cochlear
Pty Ltd). (B) A conceptual depiction of an electrode array with drug (blue diamond shapes) incorporated
within the silicone housing.

The addition of function to an existing device has advantages over the creation of an
additional device, providing the new design does not compromise existing functionality,
change its properties or create negative impacts. Acceptance of a new device does not
need to be established. Features such as the shape, size, mechanical properties and overall
integrity of the electrode array that is inserted into the cochlea must remain unchanged.

Changes in design should also not adversely affect existing procedures associated with
the device, such as surgical implantation, where complexity or surgery time should not
be increased. The re-use of existing components of implants as part of the drug delivery
system requires no additional surgical procedures.

This idea has been considered and evaluated in some literature, including by the
HEARing Cooperative Research Centre in conjunction with Cochlear itself where passive
drug elution from the electrode array was confirmed to be feasible and is currently
undergoing clinical trials (THE HEARing CRC, 2016). Other researchers have
investigated the integration of various requirements within an implantable cochlea device,
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including the need for deeper insertion, proximity to the modiolus within the cochlea and
atraumatic insertion and found no existing devices satisfy these seemingly competing
objectives (S. J. Rebscher, Hetherington, Snyder, Leake, & Bonham, 2007).

To assess the feasibility of a 3D printed integrated drug delivery cochlear implant, this
project aims to 3D print a dummy electrode array housing with embedded drug delivery
functionality. A fundamental principal of this study will be to develop a printing process
capable of printing both the existing material, and the material with the embedded drug.
Many materials require the addition of solvents to make them more suitable for printing.
The added solvents can be difficult to be remove and can cause issues when implanted.
In this particular project, the 3D printing process itself, rather than the material, will be
modified to enable printability. This is hoped to ease integration of the new production
process, if it indeed proves feasible, as the material itself will only contain the additional
drugs and no residual solvents. Only anti-inflammatory drugs, that are proven to be
effective, will be incorporated into the PDMS, creating a bio ink suitable for printing. The
dummy array will not include the electrodes at this preliminary stage.

The dummy array will be designed with multiple layers of individual struts laid down in
a rectilinear pattern. The struts will be individually printed with naked PDMS and
dexamethasone loaded PDMS (Dex-PDMS) and analysed independently. This allows
them to be combined in many varying designs, such as printing alternate layers of naked
and drug-loaded PDMS, introducing flexibility to the final design of the 3D structures.
There is however, little literature on 3D printing with PDMS. This study aims to assess
the ability to 3D print PDMS for use in implantable drug delivery devices.
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1.6.7. Aims
The aims of this study are to


Rheologically assess Cochlear PDMS and Dex-PDMS as an ink for 3D printing



Develop a method to assess the dimensions of 3D printed struts



Optimise printing protocols for Cochlear PDMS and Dex-PDMS inks



Utilise optimised protocols to 3D print Cochlear PDMS and Dex-PDMS
constructs



Evaluate drug release of a 3D printed Dex-PDMS construct

Achieving these aims will bring us closer to an understanding of whether the inclusion of
a drug-delivery function into a 3D printed drug-eluting cochlear electrode array is
possible.

The Cochlear PDMS, to be used in this study, is a Liquid Silicone Rubber (LSR) mixed
in a 10:1 ratio (10:1 LSR) from 2 parts. It is a thermoset material from the group of
polydimethylsiloxane (PDMS). PDMS is used in many implants, including the cochlear
implant. It starts as a liquid and is cross-linked via the application of heat to become a
solid elastomer. During extrusion printing, it will be processed through the printer as a
liquid, and then be cured via heat, after it is printed, to become a solid elastomer, usable
as a biomedical implant. An understanding of its behaviour throughout the process is
required, as printing with a liquid presents both useful properties and difficult
characteristics which must be overcome. At present, there is no publicly available
rheology on the specific form of 10:1 LSR used in this study. Therefore, rheological
properties are needed to inform on the suitability of both the 10:1 LSR and drug loaded
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ink for optimal 3D printing. The final printed devices may incorporate different inks, i.e.
PDMS and Dex-PDMS within different printed layers to modulate properties and
functionality.

Rheological analysis of this liquid form of 10:1 LSR will enable a detailed understanding
of its characteristics at different stages within the printing process. The ink will undergo
changes in viscosity as shear forces are applied through the extrusion process whilst it is
squeezed through the nozzle, and then removed as it is extruded onto the substrate.
Assessing the specific viscosity of the 10:1 LSR, as a function of shear stress at room
temperature allows us to consider what happens as the ink is forced under pressure
through the printing nozzle without any heating or cooling mechanisms.

An understanding of viscosity at the point where the ink is delivered to the printing plate
is also required. Here, the ink has been extruded from a cylindrical nozzle, and a tube of
ink is formed on the substrate. It is anticipated that the liquid ink is likely to spread or
slump immediately after printing, resulting in “flattened” struts that are much wider than
they are high. It is preferable that the tube maintains some circularity to its cross-section
shape to form uniform struts with spacing between them. This allows for the creation of
a strong base that can then be built upon in a layer-by-layer formation. This enables the
formation of complex and variable structures, with variable porosity and a high
resolution. Controlling this sideways flow allows us to minimize the widths of the
cylinders that are created. An opportunity exists to control the temperature at the specific
point when the ink is laid down on the substrate, by heating the substrate independently
of the extrusion syringe. A rheological assessment of how temperature affects the ink is
therefore required to ascertain appropriate printing protocols with regards to the extrusion
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head printing temperature and substrate temperature.

These same assessments will be made independently on Dex loaded 10:1 LSR (DexPDMS) to give us an understanding of any differences in behaviour. This permits
flexibility in design of 3D printed structures that may use a combination of both inks.
These designs may incorporate the use of both inks for different layers to affect features
and functionality of the printed device.

Optimised print protocols will enable the production of the finest dimensioned struts, that
will allow for the creation of structures with the smallest overall dimensions, desirable
for the intended application of this study.
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2. Materials and Methods
2.1. Materials
The form of polydimethylsiloxane (PDMS) used is a proprietary form and was obtained
from Cochlear Pty. Ltd. It is an implant grade 10:1 platinum cure liquid silicone rubber
(10:1 LSR). It is a 2 part system consisting of a liquid silicone (Part A) and a cross-linking
agent containing platinum (Part B) and is a liquid when initially mixed at room
temperature. It is activated when heat is applied. Fresh samples were prepared by
combining Part A and Part B of each batch, in a 10:1 ratio and mixing and degassing in
the Thinky ARE-250 planetary centrifugal mixer. Within this study, it is referred to as
10:1 LSR, PDMS or PDMS ink.

Micronised

dexamethasone

(USP)

was

obtained

from

Spectrum

Chemicals.

Dexamethasone was added to the freshly mixed PDMS in a 2.5% w/w Dex/PDMS weight
ratio. It was manually stirred with a spatula and then completely mixed and degassed in
the Thinky ARE-250 planetary centrifugal mixer.

Kapton® Tape, 24mm was obtained from Altronic Distributor and applied directly to
microscope slides where it was used as a printing substrate.

Artificial perilymph solution (ARF, pH 7.4) was prepared to simulate the body fluid in
the cochlea, using a one-pot synthesis approach. This comprised of NaCl (7.39 g/L),
KHCO3 (0.35 g/L), NaHCO3 (2.02 g/L), CaCl2 (0.08 g/L) and NH2C(CH2OH)3 (0.61 g/L)
into a total volume of 1000mL of deionised water and adjusted to a pH of 7.4 with HCl.
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2.2. Rheological characterisation of ink
Rheological characterisation of 10:1 LSR and dexamethasone loaded 10:1 LSR (DexPDMS) was performed to allow an understanding of the behaviour of the ink during
extrusion printing. A shear rate sweep assessed changes in viscosity during the extrusion
process. A time sweep at various changes examined storage and loss moduli to assess
behaviour during the curing process.

Rheological measurements of 10:1 LSR and Dex-PDMS were undertaken on 2
rheometers, 30 minutes after mixing. Room temperature measurements were taken on the
TA instruments AR-G2 rheometer, fitted with a 15 mm, 2º Peltier cone plate with a 55
µm truncation gap and the Peltier stage set to 25 ºC. Higher temperature measurements
were taken on the Anton Parr Physica MCR 301 fitted with a 15 mm parallel plate with
a gap distance of 200 µm, increasing to 300 µm when curing occurred too rapidly to
achieve a 200 µm gap. Loading of the rheometer stage and lowering of the plate took an
additional 60 seconds before measurements actually began. For the final experiments,
where 60 seconds became too long, i.e. when the curing occurred within this time period,
the starting height of the plate was reduced so that the lowering took only 40 seconds.

For each rheological experiment, 0.06 ml of ink, sufficient to cover the plate, was loaded
onto the stage. The head was lowered and any excess ink was removed. Between each
experiment, the stage was cleaned and a fresh sample was loaded.

A shear rate sweep was performed at 25 °C. This temperature was chosen to determine
behaviour within the extrusion printer anticipated to be performed at room temperature.
Viscosity was measured as a function of shear rate (0.1 -> 100 s-1), and consistency factor
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(K) and flow behaviour index (n) values were determined.

A time sweep at various temperatures (50 ºC, 75 ºC, 100 ºC, 120 ºC) with a constant strain
(1%) was performed, while storage and loss moduli G’ and G” were measured. The
temperatures were chosen to identify curing behaviour once the ink was laid down on the
print bed where temperature was anticipated to improve structural integrity of the struts.
The maximum temperature of 120 ºC was chosen as this was the maximum temperature
possible on the printing platform of the 3D printer used in this project.

2.3. Extrusion Printing PDMS inks
In order to create a 3D printed drug-eluting construct that mimics a cochlear implant
electrode array, an investigation of the 3D extrusion printing of PDMS and Dex-PDMS
was undertaken. This necessitated the 3D printing of individual lines (struts) of PDMS
and Dex-PDMS, characterization of those struts, 3D printing of multi-layered 3D
structures of PDMS and Dex-PDMS, and characterization of those 3D structures.

The SPS1000 Bioplotter from the Korean Institute of Machinery and Materials (KIMM)
was used to 3D print PDMS inks. The PDMS ink struts were formed via the pneumatic
extrusion of the PDMS inks through a syringe with a needle attached. Both simple single
layer and complex multi-layered structures were designed and modelled within the
Mechatronics for Technology (M4T) software used by the KIMM. A layer-by-layer
deposition mechanism was used to produce the resulting scaffolds.
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Figure 12. SPS100 Bioplotter Korean Institute of Machinery and Materials (KIMM)

PDMS was mixed in a 10:1 ratio in the Thinky mixer and loaded into a clean disposable
syringe used as an ink barrel on the KIMM. As the PDMS is liquid at room temperature,
printing was performed with the printing barrel, containing the ink, at room temperature,
30 minutes after mixing. A visual observation initially identified complete and apparently
uniform struts. Quantitative analysis of those complete struts was performed with
measurement of the resulting strand dimensions shown as a function of print speed while
also varying the nozzle internal diameter (100 µm, 150 µm) and air pressure (700 kPa,
750 kPa). A choice of various substrate materials was used to determine which could be
successfully printed on whilst also enabling intact removal of final structures.

Single lines (struts) were printed in an 11 row rectilinear formation, with 500 µm centreto-centre spacing between the struts and within a 5 mm by 5 mm square area as shown in
Figure 13 below. These 5 mm × 5 mm squares were used for the bulk of the analysis.
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Figure 13. Square design with 11 rows of rectilinear strut, 500 µm centre to centre strut distance

Multi-layered square scaffolds, as shown in Figure 14, were created to enable an
evaluation of multi-layered constructs. These 5 mm × 5 mm scaffolds were printed with
both 2 and 4 layers, with each successive layer rotated 90º to the previous layer. The layer
height was set to 0.1 mm.

Figure 14. Multi-layered square scaffold designs with 11 rectilinear struts, 500 µm centre-to-centre strut
distance in both 2 and 4 layers

Long narrow array constructs with small overall dimensions were designed to emulate
the essential geometry of the silicone housing of a cochlear implant electrode array, as
shown in Figure 15 below. Theses 15 mm long by 800 µm wide constructs, with 0.1 mm
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layer heights, were printed with both 2 and 4 layers. Each successive layer rotated 90º to
the previous layer, producing a sinusoidal pattern in the 2nd and 4th layers. This design
resulted in an uneven top surface, mimicking the top layer of a cochlear electrode array
with its alternating surface of silicone and exposed electrodes.

500 µm

500 µm

Figure 15. Long, narrow array design with both 2 and 4 layers, 500 µm centre-to-centre strut distance

As the KIMM printer does not have a laser measuring mechanism to measure the needle
height from the substrate, it was manually configured by lowering the tip to the printing
substrate before each print run and then lifting it, by the fine measurement gauge to a
distance of 10 µm from the substrate.

PDMS inks were printed at room temperature on a glass substrate. This substrate was a
glass microscope slide that enabled easy movement of the printed samples on the slide
from the printer stage to the oven for curing, to the microscope for imaging, and to the
profilometer for measuring. These glass substrates were transferred to the oven for curing
shortly after printing and cured at 140 ºC for 3 hours. The effects of printing on a room
temperature substrate and pre-heated substrate was assessed for impact on strut
dimensions. The effects of printing on a glass, Teflon, and Kapton tape surface was also
assessed for ease of removal of the structures following curing.

Once cured, the glass slides were removed from the oven and the struts and 3D constructs
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were characterized whilst on the slide. The 3D constructs were subsequently removed
from the substrate for drug release studies.

2.4. Morphological and Topographical Characterisation
2.4.1. Microscopy
A Leica M205A microscope (Leica Microsystems, Wetzlar, Germany) using the Leica
Application Suite software was used to capture images of the 3D printed struts and
scaffolds and record preliminary width measurements.

2.4.2. Profilometry
Both optical and stylus profilers were used to measure the surface profiles of printed
samples.

Stylus Profilometry
A Dektak 150 Stylus Profiler (Veeko Instruments Inc, New York) (Figure 16A) was used
to record surface profiles of single layered struts. The profiler works by bringing a
diamond tipped stylus into contact with the sample surface and moving the stage
horizontally beneath it. The mechanical movements of the stylus are converted to electric
signals, capturing the profile of the surface, as seen in Figure 16B. The tip of the stylus
has a rounded shape that can limit its accuracy when dealing with steep vertical sides of
samples and potentially result in edge distortion. The vertical measuring range of the
profiler is 1 mm with a vertical resolution of up to 1 angstrom when operating within 6.55
micron range (Veeko, 2006). Given the anticipated round nature and comparatively large
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size of these samples, the potential edge distortion was not seen as being particularly
limiting. The samples were measured with “hill and valley” scan mode and the stylus
force was set to 1 mg.

A

B
Digital Signal

Stylus

Figure 16 (A) Dektak 150 Stylus Profiler (B) Working Principles of Stylus Profilometry

Each sample, consisting of 11 parallel lines, was oriented on the profiler stage such that
the stylus ran in a perpendicular direction across each strut, capturing information about
the height and width of each strut. 6000 data points were captured for each sample. The
datapoints contained X,Z co-ordinates where X was the horizontal distance from the
starting point, and Z was the vertical height. The X co-ordinate was captured every 1 µm.
The data points were exported for further analysis.

Optical Profilometry
A Wyko® NT9100 optical profiling system (Veeko Instruments Inc, New York) (Figure
17) was used to image surface profiles and to measure widths and heights of the 3D
printed, multi-layered scaffolds. The optical profiler uses a non-contact method for
measuring surface topographies i.e. white light interferometry. The wavelength of light is
the ruler. A light beam is split and shone at a reference mirror and the surface to be
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profiled. It is then recombined, causing interference. This interference image is
interpreted against the known distance to the reference mirror and a 3D image of the
surface is created with accurate height measurements, as seen in Figure 17 below. The
results were analysed using the WYCO Vision Software.

Each sample was loaded onto the optical profilometry stage and imaged. Whilst the edges
of the struts were too steep for the optical profilometer to image accurately, maximum
heights were detectable as the highest peaks, and strut widths were identifiable. Both were
measured by the Vision software and exported for analysis.

A

B

Figure 17. (A) Veeco Wyko NT9100 Optical Profiler. (B) Working principles of an Optical Profiler
(Zygo, 2018)

2.4.3. Strut Analysis Methodology
A method was required to be developed to assess the dimensions of the individual PDMS
struts. This utilized the topological data from the stylus profilometer and algorithms
created within MS Excel to determine actual strut dimensions in terms of both width and
height.
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2.5. In-Vitro Drug Release Study of Dex-PDMS Arrays
In order to determine whether a 3D printed Dex-PDMS construct is suitable for providing
drug-delivery functionality to a cochlear implant electrode array, an assessment of
whether the drug-elution occurs from a 3D printed Dex-PDMS construct was required.

2.5.1. Method for Drug Release
A passive release study was performed on 3D printed Dex-PDMS, in the form of a dummy
electrode array, pre-loaded with 2.5% dexamethasone. The dummy array form was
chosen to mimic the approximate dimensions and surface profile of an actual Cochlear
electrode array. The surface of the actual electrode array consists of silicone along the
bottom surface with exposed electrodes on the top surface, i.e. it is not a continuous,
smooth silicone surface.

Each array was suspended in a 1.5 ml Eppendorf vial containing 1 ml of artificial
perilymph solution (ARF) and kept in a shaker water bath at 37 C. At each time interval,
the release solution was removed from the Eppendorf and replaced with 1ml of fresh
ARF. The released samples were stored at -18C until HPLC analysis was undertaken.

2.5.2. Detection of Dexamethasone Release
Dexamethasone (Dex) release was detected using high performance liquid
chromatography on the Agilent 1260 Quartenary system with an Atlantis® T3 C18
column (250 mm × 4.6 mm, 5 µm). Temperature was set to 40 C. A mobile phase of
65% deionised water and 35% acetonitrile was used. Absorbance results were detected at
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242 nm using a UV-visible detector. A sample volume of 10 µL was injected at a flow
rate of 1 ml/min and detection was calibrated to elute for 6.5 minutes.

Standard solutions were created. A stock solution of 1.0 mg of dexamethasone in 1 ml of
ethanol was made. 50 µL of this stock solution was mixed with 950 µL of filtered
Artificial Perilymph (ARF) solution to create a 1:20 solution (S1) and vortexed. 400 µL
of this solution was mixed with 400ul of ARF, and so on until 12 standards were created.
The resulting concentrations are listed in the table below.

Table 2. Dexamethasone Concentrations

Sample Name

Concentration (ng/ml)

S1

50000

S2

25000

S3

12500

S4

6250

S5

3125

S6

1562.5

S7

781.3

S8

390.6

S9

195.3

S10

97.7

S11

48.8

S12

24.4

Each standard was run against the method created for these conditions. The peak
associated with the dexamethasone was integrated and linked to its corresponding known
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dexamethasone concentration to create a calibration curve of Dex in ARF.

The drug release samples were analysed using the HPLC software utilising the new
method containing the calibration curve. The resulting peaks were integrated and
compared to the known concentration in the calibration curve, producing a table of Dex
concentrations for each sample. This data was exported from the HPLC analysis software
for further analysis. Results were expressed as mean ± SD.

2.5.3. Scanning Electron Microscopy (SEM)
Scanning electron microscopy (SEM) imaging was carried out on a FEI Helios NanoLab
G3 CX scanning electron microscope at an accelerating voltage of 5 kV. Images were
obtained to observe the surface and internal morphology of printed PDMS and DexPDMS ink. Images were also acquired, of the Dex-PDMS struts after 97 days of drug
release was performed. Fracture surfaces were prepared by freezing the samples with
liquid nitrogen and snapping them across the strut, to expose the cross sectional area.
Surface images were obtained from 3d printed samples. Suitable fragments and samples
were mounted on an aluminium support stub on conductive carbon tape (SPI products)
and sputter coated with a 10 nm platinum using a Dynavac SC100MS magnetron sputter
coater (Dynavac, Australia). SEM images were obtained in magnifications of 1000x,
1600x and 10,000x.

Elemental distribution mapping was carried out via Energy-dispersive X-ray
spectroscopy analysis using an Oxford Instruments X-maxN SSD energy dispersive Xray detector.
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3. Results and Discussions
3.1. Rheological Evaluation of PDMS and Dex-PDMS
3.1.1. Shear Rate Sweep
3D extrusion printing of inks requires them to undergo shear forces as they pass through
the printing nozzle. A shear rate sweep demonstrated a decrease in viscosity as shear rate
was increased, demonstrating non-Newtonian behaviour and the shear thinning property
of the 10:1 LSR (PDMS) ink (Figure 18), Shear thinning of the ink, that is a reduction in
viscosity as shear is applied, is desirable for extrusion printing as it allows the ink to run
more freely as it is squeezed through the nozzle, and then return to its pre-cursor viscosity
after printing when the shear forces are no longer being applied. The shear thinning
behaviour can be described by the power-law relationship. The shear thinning exponent,
as represented by the flow behaviour index, n, can be determined by fitting the viscosityshear rate curve to the power law equation (Doran, 2012):

Equation 1

𝜂 = 𝐾𝛾 𝑛−1
where,
η = Viscosity (Pa.s)
K = Consistency factor
γ = Shear Rate
n = Flow behaviour index
The results for the 10:1 LSR showed an R2 value was 0.98, when fitted to the curve,
indicating it was within 2% error. The flow behaviour index of 10:1 LSR, representing
the shear thinning exponent, n, was determined to be 0.775. This is considered to be shear
thinning, which bodes well for successful extrusion of the ink, but does not resolve flow
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issues after deposition on the substrate. The consistency factor was 89.219 Pa.s. As the
intention of the final application is to potentially print with a combination of PDMS and
Dex-PDMS inks, the same experiment was performed on the Dex loaded 10:1 LSR (DexPDMS). The Dex-PDMS demonstrated a shear thinning exponent of 0.782, but the
variation to the PDMS shear thinning value of 0.775 was insignificant. The consistency
factor was 94.195 Pa.s (Figure 18).

200

Viscosity (Pa.s)

PDMS
Dex-PDMS

y = 94.195x-0.218
y = 89.219x-0.225

20

0.1

1

Shear Rate (s -1)

10

100

Figure 18. Viscosity-shear rate curve of PDMS and Dex-PDMS

The viscosity and flow rate directly impact the stress that the ink experiences when being
extruded. To calculate the maximum shear rate experienced by the ink under extrusion
conditions, and as a result, the viscosity, the following equations have been used:

Equation 2

For Newtonian fluids

𝛾 (𝑎𝑡 𝑡ℎ𝑒 𝑤𝑎𝑙𝑙) =

Equation 3
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4𝑄
8𝑉
=
𝜋𝑅 3
𝐷

For non-Newtonian power law fluids (Mohammadi, Saffarian, & Mohammadi, 2018)

𝛾=

4𝑄 3𝑛 + 1
∙
𝜋𝑅 3
4𝑛

𝛾=

8𝑉 3𝑛 + 1
∙
𝐷
4𝑛

Or with substation from Equation 2

where,
Q = Volumetric Flow Rate
R = Radius of the nozzle
V= Velocity of extrusion
D = Diameter of nozzle
γ = Shear Rate
n = flow behaviour index (shear thinning exponent)
Equation 2 is used to calculate the shear stress of a Newtonian fluid. Shear stress of a nonNewtonian fluid is calculated by combining this equation with the Rabinowitsch
correction factor (Mohammadi et al., 2018) to give equation 3. The fluid near the centre
of the extruded ink tube moves faster than the fluid near the walls, according to the Law
of Wall principle, and so experiences the highest level of stress, whilst in the printing
nozzle. For example, when the PDMS ink is printed through a 100 µm nozzle at a rate of
100 mm/s, the calculated maximum shear rate at the centre is 753.8 s-1, which correlates
to a viscosity of 20.1 Pa.s.

With a viscosity of around 20 Pa.s, while under the shear stress of the extrusion process,
the PDMS ink will be extrudable. After extrusion, when there is no shear stress, the
viscosity of the liquid ink will return to its pre-shear viscosity of 149.8 Pa.s. In the case
of the Dex-PDMS ink, under the same condition of a 100 µm nozzle at a rate of 100 mm/s,
the calculated maximum shear rate at the walls is 721.1 s-1, which correlates to a viscosity
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of 21.3 Pa.s. These results show an insignificant difference in the viscosity and shear
thinning values between the 2 inks, indicating they should be extrudable under similar
print conditions. After extrusion, when there is no shear stress, the viscosity of the PDMS
ink will return to its pre-shear viscosity of 147.4 Pa.s assuming a shear rate of 0.1 s-1.
Whilst this is a 7 fold increase in viscosity for both inks, it is unlikely to be sufficient to
retain strut fidelity. Other studies have shown successful shape retention after 3D
extrusion printing when viscosity returns to values such as 1300 Pa.s (Tian et al., 2017).
Since the addition of modifying agents to increase viscosity is not feasible given the need
to utilize unmodified PDMS, a method to improve strut fidelity retention through
modifications to components of the print process is required.

3.1.2. Time Sweep at Various Temperatures
An increased temperature increases the cure kinetics of this 10:1 LSR form of PDMS. 3D
extrusion printing is capable of providing a heated substrate on which printing can be
performed. Printing directly onto a heated substrate may initiate the curing process in situ
and improve the fidelity of the struts by reducing their sideways slumping. It is essential
to study the effect of temperature on the curing process on this form of PDMS and use
this knowledge to establish appropriate substrate temperature control for printing
structures with optimal fidelity.

Figure 19 shows the changes in modulus of the PDMS ink as a time sweep at various
curing temperatures (50 ºC, 75 ºC, 100 ºC, 120 ºC). Each graph shows the PDMS ink as
a liquid that begins to cure over time. At 50 ºC, the storage modulus (G’) and loss modulus
(G”) of the PDMS ink increased, but did not cross or become stable within the 700 second
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time interval observed (Figure 19A). At 75 ºC, the PDMS ink began to cure more quickly.
The crossing of the lines, where G’ becomes greater than G”, identified the sol-gel
transition point of 515 seconds. The PDMS did not become stable (Figure 19B). At 100
ºC, sol-gel transition occurred at 115 seconds followed by a plateau around the 230 second
time interval, where both the storage and loss modulus became stable, demonstrating
more rapid progression towards the completion of the curing process (Figure 19C). At
120 ºC, the sol-gel transition was achieved by 50 seconds with the stability plateau
occurring around the 140 second time interval. These results demonstrate that as the
temperature is increased, the time taken for both gelation and curing is reduced, showing
that the LSR begins to cure and becomes solid more quickly at a higher temperature.

With the addition of Dex to the PDMS ink, and at a curing temperature of 120 ºC, the solgel transition occurred before the plate had completed lowering. The starting height of
the plate was decreased, reducing the lowering time from 60 seconds to 40 seconds. These
time intervals are included in the graph time axis, prior to presentation of measurement
data. The Dex-PDMS ink showed a sol-gel transition at the 50 second time interval, 20
seconds earlier than the PDMS sol-gel transition point of 70 seconds (Figure 19D). These
transition times are summarized in Table 3. The plateau around the 100 second time
interval suggests earlier curing of the Dex-PDMS ink. This suggests that the addition of
the solid Dex particles facilitates earlier solid like behaviour.

It can also be seen that storage modulus is higher for the Dex-PDMS ink with a starting
value of 1.1 kPa for PDMS ink and 2.9 kPa for the Dex-PDMS ink. The inclusion of
nanoparticles or microparticles has been shown to affect rheological behaviour due to
additional cross-linking of the polymer network (Ma, Yang, Zheng, & Song, 2017). The
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inclusion of micronised Dex particles to the PDMS ink has increased viscosity, and loss
and storage moduli both before and after curing, appearing to improve rheological
behaviour.
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Figure 19. Storage and Loss Modulus of PDMS over time at 50 °C (A), 75 °C (B), 100 °C (C) and PDMS
and Dex-PDMS at 120 °C (D).

Table 3. Sol-Gel Transition times of PDMS and Dex-PDMS ink.
Ink

50 °C

PDMS
Dex-PDMS

75 °C

100 °C

120 °C

>760 secondsA 515 secondsA

115 secondsA

70 secondsB

-

-

50 secondsB

-

A

Includes 60 second plate lowering time BIncludes 40 second plate lowering time.

These results suggest that printed PDMS and Dex-PDMS inks can undergo a rapid solgel transition if heat is applied immediately to expedite the cross-linking process after the
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PDMS strut is produced. This is at its most rapid with the highest heat setting of 120 °C.
This characteristic can be utilized in the printing process to start the sol-gel transition of
the external surface of the printed strut, sufficient to prevent spreading of the strut. This
can be accomplished by printing onto a heated substrate so that the heat is applied as soon
as the strut is extruded onto the surface. Continued application of the heat will ensure
further curing, ensuring the strut becomes structurally stable enough to support further
layers laid on top of each layer by the extrusion printer, and should increase the ambient
temperature within close proximity and immediately above the substrate to support
further layers.

3.2. Evaluation of Extrusion Printing PDMS
PDMS struts were 3D printed in 5mm × 5mm rectilinear structures consisting of 11
individual lines in a single layer as shown in Figure 20 (A). The printed struts were
examined under an optical microscope for uniformity. Uniform struts were quantitatively
analysed by measuring both height and width using the stylus profiler. Printed struts were
observed to form smooth non-circular cylindrical shapes. The lack of circularity occurred
as a result of the ink spreading sideways, or slumping, requiring that both height and
width be measured independently.

Printing parameters were fine-tuned in order to produce consistent and solid lines. The
printed struts were examined to determine the effects of print speed, air pressure, internal
needle diameter, and drug-loading on the strut dimensions. The strut dimensions were
measured and analysed as described in the following Section 3.2.1, Strut Analysis
Methodology, to determine the effects of various print conditions and optimal printing
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speed windows. Only uniform lines were measured and analysed as non-uniform lines
were considered as “failure to print”. Figure 20 (B) shows printed lines considered nonuniform (1) and uniform (2). These non-uniform lines were the result of conditions such
as insufficient air pressure. Once successful conditions were established, uniform lines
were able to be continuously produced.

Figure 20. (A) Extrusion printed 5mm × 5mm rectilinear PDMS single layer square (B) Extrusion printed
PDMS showing (1)Non-uniform and (2) uniform struts.

3.2.1. Strut Analysis Methodology
A method was required to be developed to assess the dimensions of the individual PDMS
struts and 3D scaffold structures. This utilized the topological data from the stylus
profilometer and algorithms created within MS Excel to determine actual strut
dimensions.

Struts form the basis for 3D structure creation and their individual attributes need careful
analysis. A uniformly circular cylindrical strut can be measured and quantified by its
diameter. A material that flows sideways after extrusion slumps into less circular
cylindrical struts and requires alternative measurements. The height and width of a non61 . 113

cylindrical strut can give further information about the strut. As the material slumps, the
struts becomes lower and wider. A method to measure and compare these 2 measurements
is required. Calculating the ratio between the width and height gives a reasonable
demonstration of how close the strut is to achieving circularity. The closer to 1:1 this ratio
is, the less slumping is occurring and the more likely it will be able to achieve high and
narrow 3D structures. Also, providing this ratio of height-to-width remains uniform, a
certain amount of predictability in behaviour can be assumed. It is therefore important to
measure these dimensions accurately. Surface profilometry, performed in a perpendicular
direction to the struts as shown in Figure 21 below, gives us accurate data from which we
can calculate the height and width of individual struts.

Figure 21. Schematic showing stylus direction across profile of 3D printed struts

The stylus profilometry software generated 6000 data points of XZ co-ordinates for each
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sample. These data points were imported into MS Excel. Automated algorithms were
created to calculate measurements of widths and heights of the 3D printed struts as
described in Appendix I. A diagrammatic representation of each sample profile as shown
below in Figure 22, was created to enable visual verification of the data.

Figure 22. Strut profiles created from data exported from the Stylus profilometer

Algorithms were created in MS Excel, to automate the detection of peaks (maximum
heights). This was defined as the maximum Z value achieved as a change in slope of the
curve was detected from positive to negative. This was recorded as the peak height. An
example is illustrated below in Figure 23 showing where peaks were detected in the
profile data. Results were expressed as mean ± SD.

Figure 23. Automated detection of strut peaks

Algorithms were also created to detect the start and ending edges of individual struts, as
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shown in Figure 24 below. These values were used to calculate the widths of each
individual strut. This was calculated by the detection of a change in slope from the zero
baseline to a positive gradient for the start of a strut, and a change from a negative gradient
to neutral slope for the end of the strut. Strut widths were then calculated from these start
and end points. Results were expressed as mean ± SD.

Figure 24. Auotomated detection of start and end of strut edges.

3.2.2. Effect of Substrate Temperature
Slumping of the PDMS ink struts on a room temperature substrate was identified early.
The PDMS struts visibly spread sideways immediately after printing, running into the
next strut, necessitating some modifications to the method. The rheology results
demonstrated rapid cross-linking kinetics at high heats, with sol-gel transitions beginning
within 70 seconds at temperatures of 120 °C, suggesting that heat may improve accuracy
of printing by reducing slumping but if applied to the ink whilst still within the print barrel
could cause nozzle blockages due to a thickening of the ink. This quick gelation time
also suggested that the rapid application of heat immediately after printing had the
potential to reduce slumping. Pre-heating of the printing stage was available on the
KIMM printer which in turn created a heated substrate onto which the PDMS could be
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printed, beginning the curing process as soon as the PDMS was printed. The printing
platform temperature was set to 120 ºC. Elevation of the printing substrate temperature
was shown to permit initial gelation of the PDMS on impact with the substrate, sufficient
to allow the struts to maintain some shape until final post curing could take place. The
struts printed on the heated substrate visibly slumped much less, producing struts with
more height and less width, an example of which is shown in Figure 25. It can be seen
that those struts printed on a room temperature substrate spread to a width of 609 µm,
whilst those printed on a substrate heated to 120 °C were limited to a width of 230 µm.
The resulting cylindrical strut was not perfectly circular but was significantly narrower.
The rising heat did cause nozzle blockages, due to the thickening of the PDMS within the
nozzle, but enabled up to 20 minutes of printing time. A temporary heat shield was applied
to the printing nozzle to deflect some of this heat and allow the printing to proceed, but it
showed no significant extension of print time.

Figure 25. (A) Cochlear PDMS printed at 700 kPa air pressure with a needle internal diameter of 100 µm
at 100 mm/s print speed on a room temperature substrate with a width of 609 µm. (B) Cochlear PDMS
printed at 700 kPa air pressure with a needle internal diameter of 100 µm at 100 mm/s print speed on a
substrate heated to 120 °C with a width of 230 µm.
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3.2.3. Effect of Substrate Material Choice
Printing was performed on glass microscope slides. After curing in an oven at 140 °C, the
struts could not be removed from the glass microscope slide without breakage due to the
adhesive qualities of the PDMS. Alternative substrate materials were considered to allow
for the removal of the cured PDMS. A Teflon substrate was trialed but the PDMS was
unable to adhere during the printing process. Kapton tape, is a smooth polyimide film,
yellow-gold in colour, which can be applied to a surface and is stable across a wide range
of temperatures. It was trialed for its anticipated sufficiency in surface adhesion during
the print, resistance to the heat applied during the curing process, and subsequent easy
removal of the cured PDMS. It was applied to the surface of the glass microscope slide,
and created a surface that was successful for both printing and structure removal.

Once cured, the Kapton-glass slides were removed from the oven and the struts and 3D
constructs were characterized whilst on the slide. The 3D constructs were subsequently
easily removed from the Kapton tape surface for drug release studies.

3.2.4. Effect of Print Speed on PDMS Strut Dimensions
Extrusion printing was performed with 10:1 LSR (PDMS), utilizing a 100 µm diameter
needle at a pressure of 700 kPa, onto a printing stage heated to 120 C at various print
speeds. A 100 µm diameter needle was chosen as the smallest needle available and was
expected to produce the smallest dimensioned struts. Rheological analysis showed a high
viscosity and thus predicted difficulty in extruding through a small diameter needle. 700
kPa of pressure was identified as the minimum amount of pressure required to extrude
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the PDMS ink through this needle. The heat setting of 120 C was the maximum available
on the printing substrate for the KIMM printer with this same temperature showing a
rapid sol-gel transition for this ink. Print speed was increased until a visible line formed.
The minimum setting required for the formation of a uniform line was 20 mm/s. This was
gradually increased until a maximum speed of 300mm/s was achieved where solid lines
were failed to be produced. Beyond this print speed, solid uniform PDMS lines also broke
up and did not appear as consistent and uniform.

The effect on single strut dimensions of increasing print speeds from 20 mm/s to 300
mm/s was quantified using the strut analysis methodology, as previously described in
Section 3.2.1, with average height values at each print speed plotted in the graph (Figure
26). This graph shows an exponential-like reduction in the height of the struts as print
speed increased. This was anticipated as a result of the same volume of ink being extruded
over a greater distance as the needle moved more rapidly. At the bottom end of the print
speed variation, at a very low print speed of 20 mm/s, a bigger height difference relative
to the small change in speed was noted.
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Figure 26. Strut height of printed PDMS as a function of printing speed printed at a pressure of 700 kPa,
with a needle internal diameter of 100 µm on a substrate heated to 120 °C. N=33
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As print speed was increased from 20 mm/s to 30 mm/s, an increase in strut width was
observed, as seen in Figure 27. As print speed was further increased from 30 mm/s to
300mm/s, the struts became narrower. The narrowing of widths as extrusion rate
decreased was seen to occur over the majority of print speeds. As the strut width
decreased, the external surface of the strut is reduced and the amount of time to cure is
also likely to be reduced, leading to a faster cure rate. This may assist in reducing the
sideways slumping of struts and further reduce their width but the extrusion rate appears
to dominate. At the lowest print speed, where extrusion rate is at its highest, the strut was
narrower. It appears that the strut cure rate exceeded the extrusion rate, and the curing
rate dominated the behaviour, resulting in higher and narrower struts. Printing within a
printing speed window of 30 mm/s – 300 mm/s correlates with dominant extrusion rate

Width (µm)

behaviour and allows for comparisons with other printing conditions.
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Figure 27. Strut width of printed PDMS as a function of printing speed printed at a pressure of 700 kPa,
with a needle internal diameter of 100 µm on a substrate heated to 120C. N=33

Graphs of height versus width of struts showed a linear increase (Figure 28A), while the
height-to-width ratio remained reasonably consistent over most of the speed range (with
the exception of 20 mm/s) (Figure 26B). Figure 26A shows the strut height was
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significantly less that the width, with values ranging from 24 – 74 µm and 137 – 417 µm,
respectively. Related to this, the average ratio was 0.18:1, where a 1:1 ratio would
demonstrate a circular cylindrical strut, thus confirming that the struts in fact adopt more
of a flattened oval morphology on the surface.

At the slowest print speed of 20 mm/s the height-to-width ratio deviates from the average
value by showing a sharp increase, i.e. height increase accompanied by decrease in width
(Figure 28B). This possibly relates to curing rates exceeding extrusion rates.
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Figure 28. (A) Height vs width of printed PDMS struts at pressure of 700 kPa with a needle internal
diameter of 100 µm on a substrate heated to 120 C within print speed window of 30-300 mm/s. (B)
Height-to-width ratio of PDMS struts produced at each print speed with pressure of 700 kPa and needle
internal diameter of 100 µm, onto a substrate heated to 120 °C. N=33

Overall, when 3D printing the PDMS ink, an increase in speed generated narrower and
lower struts with a consistent height-to-width ratio ratio as print speed increased within
the range of 30 – 300 mm/s of which provides a preferred ‘window’ of print speeds.
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3.2.5. Effect of Air Pressure at Varying Print Speeds
Rheological analysis showed the PDMS had a high viscosity of 149.8 Pa.s at room
temperature, and thus predicted difficulty in extruding through a small diameter needle.
To overcome this, the use of high air pressures within the extrusion printer was
anticipated. In this case, increasing the air pressure causes the ink to flow more easily
through the nozzle but at increasing rates, which may cause an increase in strut
dimensions. The minimum air pressure required to start the flow of ink was 700 kPa and
was determined by increasing the pressure until a stable flow of ink was produced from
the 100 µm diameter needle. It should be noted that this is a very high air pressure when
compared with extrusion printing of other materials. Typical extrusion air pressures are
examined across a range of 1-5 bar (Billiet, Gevaert, De Schryver, Cornelissen, &
Dubruel, 2014), where 700 kPa equates to 7 bar. The maximum achievable air pressure
on the KIMM printer was 750 kPa. Beyond this rate, air leakages occurred and the
pressure could not be increased further. These 2 air pressures of 700 kPa and 750 kPa
were investigated as a function of the printing speed within the range of 20 – 300 mm/s.

Figure 29 shows an exponential like decrease in height, with a sharp decrease between 20
and 30 mm/s, when printed at 750 kPa. There was a general increase in height at all speeds
when compared with those printed at 700 kPa. This correlates well with the expected
increase in volume of ink through the needle. The increased pressure did, however,
produce a sudden increase in height at 300 mm/s in contrast to the 700 KPa, which
maintained a downward trend.
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Figure 29. Strut height of printed PDMS as a function of printing speed printed at a pressure of 700 kPa
and 750 kPa, with a needle internal diameter of 100 µm on a substrate heated to 120C. N=33

At the increased pressure of 750 kPa, the width showed a decrease with increasing print
speed increased (Figure 30). Interestingly, the previously observed increase in width as
print speed increased from 20 mm/s to 30 mm/s at 700 kPa was not evident at 750 kPa,
which in contrast, showed significant decrease in the values. In addition, the width of the
struts was greater than those produced at the lower 700 kPa across all print speeds (Figure
30), correlating well with the expected increase in volume of ink through the needle at
higher pressures.

Similar to the height, the width also appeared to suddenly increase when printed at 300
mm/s. As volume of deposited ink was expected to decrease with increasing print speed,
an exact reason for this observation is not clear at this stage.
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Figure 30. Strut width of printed PDMS as a function of printing speed printed at a pressure of 700 kPa
and 750 kPa, with a needle internal diameter of 100 µm on a substrate heated to 120 C.

Figure 31 (A) shows graphs of height versus width of struts produced. Overall, when
printed with the print window of 30-300mm/s, narrower PDMS struts are produced at the
lower air pressure of 700 kPa which correlates to a lower extrusion rate of ink. Higher
struts are also generated than struts at the same width at the lower air pressure.

Figure 31 (B) shows that, across most speeds, a slightly higher height-to-width ratio of
0.18 : 1 is achieved with the lower 700 kPa pressure when compared with 0.17 : 1 at the
higher pressure of 750 kPa. At the slowest print speed of 20 mm/s, this ratio significantly
increases for both air pressures, which again possibly relates to sol-gel transition rates
exceeding extrusion rates.
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Figure 31. (A) Height vs width of printed PDMS struts at pressures of 700 kPa and 750 kPa with a needle
internal diameter of 100 µm on a substrate heated to 120C within print window speeds of 30 – 300 mm/s
and 20-200 mm/s respectively. (B) Height-to-width ratio of printed PDMS struts at pressures of 700 kPa
and 750 kPa with a needle internal diameter of 100 µm on a substrate heated to 120C across print
speeds of 20mm/s to 300 mm/s.

These results suggest that when considering air pressure, a lower air pressure of 700 kPa
produces struts with a slightly better height-to-width ratio, desirable for this study. This
greater height-to-width ratio at the lower air pressure produces more circular struts. This
higher ratio is preferred for building structures with an overall narrow width.
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3.2.6. Effect of Needle Diameter at Varying Print Speeds
Printing with 2 different sized needles was performed to compare the effects on strut
dimensions. Printing was performed with both a 100 µm and 150 µm internal diameter
needle for comparison. Figure 32 shows slightly higher struts were produced by a 150 µm
needle when compared with a 100 µm needle, under the same printing conditions across
most print speeds. At higher print speeds of 300 mm/s, the larger 150 µm needle
maintained a trend of decreasing strut height whereas the smaller diameter needle showed
an increase in values, as mentioned above. At lower print speeds of 20 mm/s, the larger
150 µm needle produced struts that unexpectedly became lower (compared to 30 mm/s)
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Figure 32. Strut height of printed PDMS as a function of printing speed printed at a pressure of 750 kPa
with a needle internal diameter of 100 µm and 150 µm on a substrate heated to 120C.

The widths of the struts was very similar for both needles within the print speed of 50 –
200 mm/s but again deviated at the lowest and highest print speeds (Figure 33). Like the
height data, the 150 µm needle continued to show a gradual decrease at 300 mm/s while
a sharp decrease was observed when the speed was reduced from 30 mm/s to 20 mm/s,
both of which were opposite to that observed for the 150 µm needle. In particular, at the
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slower print speeds, the 150 µm needle produced strut widths exceeding the 500 µm
spacing of the individual struts within the single layer design and joined together. They
were reprinted with slightly wider spacing to enable their measurement. As with the
reduction of height when printed at slow speeds of 20 mm/s, printing with the larger 150
µm needle produced narrower struts at low speeds. At higher print speeds of 300 mm/s,
the larger 150 µm needle was able to maintain its trend of producing narrower struts where
the smaller 100 µm diameter needle had failed to maintain its downward trend.
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Figure 33. Strut width of printed PDMS as a function of printing speed printed at a pressure of 750 kPa
with a needle internal diameter of 100 µm and 150 µm on a substrate heated to 120C.

Figure 34(A) shows that when a larger 150 µm diameter needle is used to print PDMS
struts at a pressure of 750 kPa, within a print window of 30 – 300 mm/s, greater strut
heights can be achieved compared to the smaller 100 µm diameter needle. This advantage
in height is lost when wider struts are produced.

Figure 34(B) shows that across all speeds, a higher height-to-width ratio is achieved when
printing PDMS with the larger 150 µm diameter needle at this 750 kPa air pressure. The
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average height-to-width ratio achieved is 0.23 with the larger needle when compared with
0.19 for the smaller needle. The best height-to-width ratio of 0.29 is achieved at the
slowest print speed of 20 mm/s.
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Figure 34. (A) Height vs width of printed PDMS struts at pressure of 750 kPa with a needle internal
diameter of 100 µm and 150 µm on a substrate heated to 120 C within print window speeds of 30 – 300
mm/s. (B) Height-to-width ratio of printed PDMS struts at pressure of 750 kPa with a needle internal
diameter of 100 µm and 150 µm on a substrate heated to 120C across print speeds of 20mm/s to 300 mm/s.

These results show the larger 150 µm gauge needle provided the better height-to-width
ratio when printed with an air pressure of 750 kPa.
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3.2.7. Effect of Drug-Loading at Varying Print Speeds
Dexamethasone (Dex) was added to the PDMS at a concentration of 2.5% to produce
Dex-PDMS ink. Struts were printed at both 700 kPa and 750 kPa of air pressure for
comparison with the non-drug-loaded struts printed under the same conditions. An
internal diameter 100 µm needle was used to generate struts with the smallest predicted
dimensions. The effect across print speeds from 20mm/s to 300mm/s was examined using
the same analysis methodology, as previously described.

The printing of Dex-PDMS struts with an air pressure of 700 kPa showed a reduction in
the strut height with increasing print speed (Figure 35). This reduction in height with
increasing print speed followed the same trend as that seen with the PDMS ink struts but
appeared to produce a smoother exponential-like curve. The printing of Dex-PDMS
produced slightly lower struts than naked PDMS ink, across all print speeds except 100

Height (µm)

mm/s.

120

700 kPa 100 µm needle

100

700 kPa 100 µm needle + Dex
120°C

80

60
40
20
0
0

50

100

150

200

250

300

Print speed (mm/s)

Figure 35. Strut height of printed PDMS and Dex-PDMS as a function of printing speed printed at a
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pressure of 700 kPa with a 100 µm internal diameter needle on a substrate heated to 120 °C.

The widths of Dex-PDMS struts were seen to decrease with increasing print speeds with
lower values compared to PDMS specifically at lower print speeds of 30-100 mm/s
(Figure 36). This observed deviation in width may be as a result of a combination of
factors. Dex-PDMS was shown to have a slightly higher viscosity of 149.8 Pa.s when
compared with PDMS with 147.4 Pa.s (Figure 18) which may be a slight contributing
factor. Dex-PDMS had a higher storage modulus of 2.8 kPa than PDMS with 1.1 kPa
(Figure 19). Dex-PDMS was also able to begin to cure more quickly than PDMS with
sol-gel transition occurring 20 seconds earlier when heated to 120 °C (Table 3). These
factors may slow the spread of the ink on the substrate and contribute to the production
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of narrower struts. Further experiments are required to identify the contributing factors.
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Figure 36. Strut width of printed PDMS and Dex-PDMS as a function of printing speed printed at a
pressure of 700 kPa with a 100 µm internal diameter needle on a substrate heated to 120 °C

This decrease in strut width, which is advantageous for enabling higher print resolution,
can be visually observed in images of PDMS (Figure 37(A)) and Dex-PDMS (Figure
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37(B)), printed under the same conditions. In this example, the Dex-PDMS ink produced
noticeably narrower struts of 303 µm when compared with the PDMS struts of 448 µm.

Figure 37.(A) Strut width of 3D printed PDMS struts at a pressure of 700 kPa with a 100 µm internal
diameter needle at 30 mm/s print speed on a substrate heated to 120 °C (B) Strut width 3D printed DexPDMS struts at a pressure of 700 kPa with a 100 µm internal diameter needle at 30mm/s print speed on a
substrate heated to 120 °C.

A graph of height versus width of struts (Figure 38 (A)) shows that generally, higher struts
are produced by the Dex-PDMS ink than the PDMS ink at the same width when printed
at an air pressure of 700 kPa.

Figure 38 (B) shows that at 20 mm/s and 200 mm/s, PDMS achieves a higher height-towidth ratio. At speeds from 30 – 100 mm/s, and again at 300mm/s a higher height-towidth ratio is achieved with the Dex-PDMS ink. The improved higher aspect ratio across
the majority of print speeds, may be due to the increased viscoelasticity of Dex-PDMS,
as demonstrated in both viscosity and shear storage moduli G’, allowing the ink to spread
less after it is laid down on the heated substrate. In addition, the more rapid curing
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behavior of DEX-PDMS also prevents the strut from spreading and contributes to the
height-to-width ratios. Struts with the greatest height-to-width ratio of 0.28:1 were
achieved at print speed of 100 mm/s with the Dex-PDMS ink.
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Figure 38. (A) Height vs width of printed PDMS and Dex-PDMS struts printed at a pressure of 700 kPa
with a 100 µm internal diameter needle on a substrate heated to 120 C within print window speeds of 20300 mm/s(PDMS) and 30 – 300 mm/s(Dex-PDMS). (B). Height-to-width ratio of printed PDMS and DexPDMS struts at pressure of 700 kPa with a needle internal diameter of 100 µm on a substrate heated to
120C.
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Dex-PDMS struts were then printed at a higher air pressure of 750 kPa of air pressure
using an internal diameter 100 µm needle. A reduction in both height (Figure 39) and
width (Figure 40), with increasing print speed, was shown. When compared to the PDMS
printed under the same conditions, the Dex-PDMS showed a similar profile, with the
addition of Dex resulting in an overall slight decrease in strut height (Figure 37) and strut
width (Figure 40). Smaller height variations at the lowest and highest print speeds were
noted (Figure 40). As described above, the smaller struts may also be as a result of a
combination of the slightly higher viscosity of the Dex-PDMS and the quicker
achievement of sol-gel transition identified by the rheology.
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Figure 39. Strut height of PDMS and Dex-PDMS as a function of printing speed printed at a pressure of
750 kPa with a 100 µm internal diameter needle on a substrate heated to 120C.
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Figure 40. Strut width of printed PDMS and Dex-PDMS as a function of printing speed printed at a
pressure of 750 kPa with a 100 µm internal diameter needle on a substrate heated to 120C.

Whilst the Dex-PDMS struts have a smaller height at the same print speed, a comparison
with a PDMS strut of the same width shows an increase in the height achieved of the DexPDMS strut (Figure 41 (A)). This improved height-to-width ratio is shown in Figure 41
(B). Across most speeds, a slightly higher height-to-width ratio is achieved with the DexPDMS ink with a very good height-to-width ratio of 0.28 : 1 at very low speed of 20
mm/s. The taller and narrower dimensioned Dex-PDMS struts may be due, in part, to the
reduced curing time of Dex-PDMS, allowing the ink to pass through the sol-gel transition
point and stop spreading more quickly after it is laid down on the heated substrate. The
higher viscosity of the Dex-PDMS may also result in a reduced flow of ink from the print
nozzle.
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Figure 41. (A) Height vs width of printed PDMS and Dex-PDMS struts printed at a pressure of 750 kPa
with a 100 µm internal diameter needle on a substrate heated to 120C within print window speeds of 20300 mm/s(PDMS) and 30 – 300 mm/s(Dex-PDMS). (B). Height-to-width ratio of printed PDMS and DexPDMS struts at pressure of 750 kPa with a needle internal diameter of 100 µm on a substrate heated to
120 °C.

In summary, 3D extrusion printing of the PDMS and Dex-PDMS ink struts was
achievable. The achievement of small resolutions was however, difficult. Much
exploration of various parameters and strategies was required to attain consistent struts.
Slumping of the PDMS was visibly noticeable immediately after printing, but had been
anticipated by the room temperature viscosity rheological measurements. The struts
showed erratic formations and ran into each other, appearing very flat and wide. Higher
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struts with narrower widths and better height-to-width ratios were desirable to enable the
production of small resolutions and narrower overall structures. The provision of a heated
substrate reduced this slumping very effectively with the heat cured PDMS. The lowest
air pressure capable of producing struts was 700 kPa. This also produced the smaller struts
as desired. A smaller diameter needle of 100 µm also produced the smaller struts. The
addition of Dex to the PDMS ink further improved the strut dimensions and delivered
more consistent behaviour.

3.2.8. 3D Structure Analysis
For 3D printed scaffolds for use as drug-delivery devices, an understanding of the
structures capable of being produced by PDMS and Dex-PDMS inks, was needed. These
structures are required to be small and have a fine resolution, meaning that the struts need
to be small, and that the vertical height consists of many layers. This building up of layers
is capable of creating complex structures suitable for devices designed for specific
placement where final shape is critical and for drug delivery, where features such as
surface area can be dramatically affected by porous multi-layered structures.

Utilising the results of printing individual struts, an investigation into the effects on total
structure height of building vertically with successive layers, was performed. 3D printing
structures with the PDMS inks was expected to prove challenging in terms of its ability
to retain its shape fidelity which could in turn affect its ability to support successive layers.

Printing of multi-layered structures was performed on a heated substrate. Strut analysis
results in the previous section showed that the application of lower air pressure with the
smallest sized needles produced the smallest struts. This suggests that in order to achieve
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fine resolution structures, we needed to print under these same conditions. For this reason,
printing protocols of 700 kPa air pressure, with a 100 µm an internal diameter needle on
a 120 °C heated substrate were chosen. Exploration of a printing speed range of between
30 – 200 mm/s was required to ascertain structure integrity above the first layer of
printing. The application of heat to the substrate was deemed necessary to not only
prevent the slumping of the ink and keeping struts to a minimum width, but to also enable
sufficient curing to provide a structural stability to the struts to allow them to support
successive layers printed on top of them. The lower air pressure was anticipated to be
required to minimize forces from successive layers disrupting the structural integrity of
the layers below.

2 and 4 layer 3D constructs were imaged with the optical profilometer. Colours within
the resulting images depicted varying heights within the structure and allowed for quick
and easy observation of trends and identification of specific peaks to be measured. The
images were visually assessed to determine trends and behaviours such as what occurred
at strut cross over points and between struts. More detailed surface statistics were
available across the entire surface. Positioning of cursors at particular peaks revealed
actual peak heights. These measurements were captured in MS Excel and graphed

Both PDMS and Dex-PDMS inks were evaluated individually as structural support struts
to allow for variation in drug delivery device designs, such as alternating drug and nondrug loaded layers.

3.2.8.1.

3D Printing Square Cochlear PDMS Structures

PDMS was printed in a rectilinear pattern in a 5 × 5 mm square shape, using 700 kPa air
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pressure, with a 100 µm internal diameter needle at speeds between 30 – 100 mm/s. The
3D structure was created in both a 2 and 4 layer form with a layer thickness set to 0.1mm.
Within these structures, initial layers were laid down left to right, with subsequent layers
rotated at 90º to that layer preceding it. The first layer was printed on the flat surface of
the substrate but subsequent layers were printed on top of the previous layer so were
printed onto an uneven surface. As the struts passed between the struts of the preceding
layer, they were observed to slump. This was anticipated but often resulted in incomplete
struts which were not suitable for supporting stable structures. High speeds appeared to
exacerbate this effect, which was observed to occur at speeds above 50 mm/s. Print
protocols were optimised by reducing print speeds to prevent the occurrence of
incomplete struts. A print window of 30-50 mm/s was determined for the 2nd layer of the
structure, in order to produce 3D PDMS structures with complete struts on all layers.
Images of 2 layer structures were taken and visually observed, appearing reasonably
uniform, as shown below in Figure 42.

Figure 42. (A) 2 layer PDMS square structures printed at 700kPa pressure with 100 µm internal
diameter needle on 120 °C heated substrate at 30 - 40 mm/s, layer thickness 0.1mm.(B) magnified

4 layer square structures were also printed. It was observed that the 4th layers were
incomplete when printed beyond speeds of 40 mm/s, reducing the effective print speed
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window to 30-40 mm/s.

Profilometry data was gathered to determine structural measurements (Figure 43).
Maximum height was measured as the highest single point on the whole structure. These
points were found where the struts crossed over each other. The diagram below, exported
from the VISION software for the optical profilometer, uses colour representations of the
different heights within the structure and shows visually the locations of these high cross
over points (coloured in red) (Figure 43).

Figure 43. Optical Profilometry image of 3D printed 2 layer PDMS 5 × 5 mm square construct

Height and width measurements were collated from 2 and 4 layer square PDMS
constructs and analysis showed an average maximum height of 133.5 ± 12.5 µm for the
2 layer PDMS, and 201 ± 56 µm average maximum height for the 4 layer PDMS
structures (Figure 44). Average strut widths were 391 ± 82 µm and 315 ± 89 µm for the
2 and 4 layer square PDMS constructs, respectively.
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Figure 44. Average maximum structure height of 2 and 4 layer square PDMS structures printed at 700
kPa air pressure with a 100 µm internal diameter needle on a substrate heated to 120C at 30-50 mm/s
print speed. N=3

3.2.8.2.

3D Printing Square Dex-PDMS Structures

Structure production was further explored with the addition of Dex to the PDMS ink.
Both 2 layer and 4 layer Dex-PDMS square structures were printed and imaged on the
optical profilometer. Figure 45 shows an optical microscopic image used to make a visual
assessment of a 2 layered 3D printed Dex-PDMS structure. This image shows clean strut
delineation, structure formation and a seemingly homogenous distribution of Dex within
the PDMS struts. Note that the yellow colouring occurs from Kapton tape on which the
struts are printed. The slumping of the 2nd layer struts allows them to wrap neatly around
the lower layer, suggesting the creation of a flatter top surface profile.
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Figure 45. 2 layer Dex-PDMS square scaffold printed at 700kPa pressure with 100 µm internal diameter
needle on 120 °C heated substrate at 30 - 40 mm/s, layer thickness 0.1mm

Measurements from the optical profilometer images gave an average maximum structure
height of 109 ± 4 µm for the 2 layer Dex-PDMS structures and 255 ± 36 µm for the 4
layer Dex-PDMS (Figure 46). Average strut widths were 389 ± 77 µm and 341 ± 57 µm
for the PDMS and Dex-PDMS structures, respectively.
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Figure 46. Maximum structure height of 2 and 4 layer Dex-PDMS structures 700 kPa with a 100 µm
internal diameter needle on a substrate heated to 120 C at 30-50 mm/s print speed. N=3

It is interesting to note that the whilst the 2 layer Dex-PDMS structures were lower in
height than the PDMS structures, the 4 layer Dex-PDMS structures were higher than the
4 layer Dex structures, but these differences were not significant. Further experiments
would be required to determine if a trend exists.

3.2.8.3.

3D Printing Dummy-Array Dex-PDMS Structures

Long narrow PDMS structures, with dimensions designed to mimic a cochlear implant
electrode array, were also printed. These dummy arrays were printed at 700 kPa air
pressure, with a 100 µm internal diameter needle at speeds between 30 – 100 mm/s, with
both 2 and 4 layers. Images below show examples of a microscopy image of the 2 layer
PDMS array structure (Figure 47 A) and corresponding optical profilometry images
(Figure 47 B and C). The microscopy image shows a uniform scaffold with the 2nd layer
sitting cleanly on the first. The optical profilometry images show colour coded heights
that indicate the general evenness of the height of the overall structure in this
configuration. This appeared to be due to less slumping between the struts in this
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particular design formation.

A

B

C

Figure 47. (A) Leica microscope image of 2 layer PDMS dummy array , (B), (C) optical profilometry
images of 2 layer PDMS dummy array

Previously, in rectilinear square designs, high print speeds had resulted in slumping
between struts that then became incomplete in 2nd and subsequent layers, enforcing the
use of low print speeds. In response to the reduced slumping effect observed in this
design, higher print speeds were briefly explored with just one sample of the array
configuration. Printing structures in this array formation produced structures of reduced
heights as printing speed increased (Figure 46). This was anticipated as a result of the
accumulation of the lower individual struts produced at higher speeds, previously
demonstrated. Figure 48 below shows a 2 layer dummy array structure achieving a height
137 µm and a 4 layer array achieving 188 µm in height with corresponding strut widths
of 326 µm and 259 µm respectively.
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Figure 48. Maximum structure height of 2 and 4 layer PDMS arrays printed at 700 kPa with internal
diameter 100 µm

These results demonstrated that different narrow structures were indeed possible and that
structure shapes could also affect the resulting heights of structures.

3.3. In-Vitro Drug Release Study of Dex-PDMS Arrays
3.3.1. Detection of Release of Dexamethasone from 3D Printed
Dex-PDMS
2.5% dexamethasone loaded 10:1 LSR (Dex-PDMS) 4 layer arrays were printed with a
100 µm internal diameter needle, 700 kPa air pressure and at a print speed of 30 mm/s.
These print protocols were chosen to produce the highest and narrowest structures, most
similar in dimensions to a cochlear electrode array. The arrays were incubated for 97 days
in an artificial perilymph solution (ARF, pH 7.4) to demonstrate long-term potential of
drug release from PDMS. These samples, an example of which is shown below in Figure
49, were each approximately 15-16 mm long, 800-900 µm wide and 4 layers high
measuring 320-380 µm in total height. Each alternate layer was printed in a 90 degree
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orientation in a sinusoidal pattern.

Figure 49. 3D printed 2.5% Dexamethasone loaded PDMS 4 layer dummy-electrode array printed at
700kPa pressure with 100 µm internal diameter needle on 120 °C heated substrate at a print speed of 30
mm/s, layer thickness 0.1mm,

Each sample was accurately weighed with results shown in Table 4 below.

Table 4. Weighed mass of 3D printed, 4 layer, Dex-PDMS arrays.

Sample Name

Weight (mg)

Sample 1

3.23

Sample 2

3.41

Sample 3

3.44

Sample 4

2.96

A calibration curve for dexamethasone in ARF was produced and utilized to determine
dexamethasone concentrations in the release solutions. As each sample had a slightly
different mass, the amount of dexamethasone released was normalised to allow for
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comparisons. A homogeneous distribution of drug molecules in the PDMS was assumed.
The dexamethasone release was calculated as a both a percentage of total drug within
each printed sample (calculated and normalised), and as an amount per mg of Dex-PDMS
array as follows.

Md = Dtotal * Mtotal

Md = Actual Mass of drug in sample
Dtotal = Amount of drug (%)
Mtotal = Total mass of array
Dr=Dd/Md

Dr=Drug Released (%)
Dd=Drug Detected

The addition of successive amounts of drug released allows us to view cumulative drug
release over time. Expressed as a percentage we can view the total amount of drug being
released over time proportional to the amount contained within the array, and also with
reference to the amount per mg of the 3D printed Dex-PDMS sample.

Figure 50 shows the cumulative amount of Dex released as a percentage of total Dex
within the Dex-PDMS array. The release profile demonstrated a burst release in the first
24 hour period. 5.6 ± 0.4 % release of total Dex was achieved by day 3. A steady release
continued until around day 24 where a plateau appeared to occur. An increase in release
was then observed around day 65, culminating in 27.7 ± 0.3 % total Dex released by day
97.
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The initial steep release of Dex can most likely be attributed to the immediate dissolution
of the micronized dexamethasone on the surface of the Dex-PDMS construct into the
ARF solution. Further time enables progressive dissolution of the micronized Dex on the
surface of the 3D printed structure. This process of the solubilisation of the Dex micro
particles leaves tiny holes in the surface where the dexamethasone microcrystals were
embedded. During that process, voids produced due to dissolution of surface dex are
created within the construct and aqueous pathways form. The plateauing in the release
rate can be ascribed to the reduced availability of Dex on the surface and the time taken
for the ARF to permeate these pathways. As more solute is able to permeate, the release
from the micronized Dex within the construct becomes more dominant. These processes
enable a sustained drug delivery mechanism.

Figure 50 also shows the cumulative amount of Dex released per mg of Dex-PDMS, i.e.
per mg of the whole array structure. A maximum release of 892 ± 21 ng of Dex per mg
of Dex-PDMS was released in the first 24 hours. Release rates slowed after this initial
burst to a steady release over the period between days 6 and 24. Whilst individual daily
release rates are not known, an average rate of ~112 ng per day per mg of Dex-PDMS,
over the 18 day period, can be inferred. The total amount of Dex released per mg of DexPDMS array at day 97 was 6987 ± 45 ng.

As a comparison, this release study shows a release value of around 14% at day 30 where
other studies have shown around 5% release rates of steroids from solid rod shaped
formations (8 mm x 1.5 mm diameter) of silicones at day 30 (Weaver et al., 2015). Such
a difference could be due to the variation in the surface/volume ratio, ie the 3D printed
samples have a larger surface area to interface with the release medium. Surface area to
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volume ratio has been shown to directly impact drug release (Alvaro Goyanes et al.,
2015), and specifically to affect Dex release from 10:1 LSR during the burst phase
(Farahmand Ghavi, Mirzadeh, Imani, Jolly, & Farhadi, 2010). The geometry of the arrays
in this study consisted of struts with gaps between each linear row and a rotation of 90°
on every second layer in a sinusoidal pattern. This porous structure results in a higher
surface area to volume ratio than a solid form with the same outer dimensions suggesting
this is a contributing factor to the higher release rate observed in this study.
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Figure 50. Cumulative Dex release as a percentage of total Dex and cumulative Dex release per mg of
Dex-PDMS in artificial perilymph at 37°C for 97 days. N=4. Error bars represent standard deviation.

Information about the local delivery of Dex within the cochlea is currently only available
in one clinical trial (ClinicalTrials.gov Identifier: NCT02905305). There is no published
information on required concentrations of Dex for local delivery. This makes it difficult
to determine actual concentrations to determine sufficient doses to achieve required
responses in humans, whilst avoiding toxic effects (Scheper et al., 2017). The toxicity
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relates to the potential effects on spiral ganglion neurons, which are the nerve cells in the
auditory pathway responsible for receiving electrical stimulation from cochlear implants.
Studies have shown reductions in impedances and fibrous tissue growth in silicone
implants with 1% and 10% Dex loadings in animal models (Wilk et al., 2016). In these
studies, average release rates of 16 ng/day and 49 ng/day were achieved, with maximum
release amounts in the order of 166 ng/day within the first 5 days for the 10% Dex loaded
implants. These results demonstrated a biologically active amount of Dex being released
into the cochlea. 3D printing offers flexibility is design with the capacity to modify and
improve release behaviour to meet the requirements of the targeted application.

3.3.2. Internal Morphology of 3D Printed PDMS and DexPDMS
Fractured cross-sectional surfaces of the 3D printed PDMS and Dex-PDMS were
prepared and investigated by SEM. As shown in Figure 51, the naked PDMS cross-section
(A,B,C) appears homogenous and smooth. The pre-release Dex-PDMS cross-section
(D,E,F) shows a rougher surface morphology, with particles embedded within cavities.
These particles are likely to be Dex particles, which was later demonstrated by chemical
composition analysis. The post release Dex-PDMS images (G, H, I) show empty cavities,
as a result of drug elution.
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Figure 51. SEM images of cross section surfaces of (A,B,C) PDMS (D,E,F) Dex-PDMS and (G,H,I) DexPDMS Post-Release structures at x1000, x1600 and x10000 magnifications.

Examination of the surface, shown at 10,000x magnification in Figure 52, emphasizes
similar morphological features to those in the fractured cross section. The PDMS ink
(Figure 52A) shows a slightly wrinkled surface with no visible particles or cavities.
Visible particles are shown on the Dex-PDMS (Figure 52B) before drug release. Empty
pores are visible in the Dex-PDMS (Figure 52C) post drug-release.
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C

10 µm

10 µm

Figure 52. SEM images of surface of (A) PDMS, (B) Dex-PDMS and (C) Dex-PDMS Post-Release
structures at x10000 magnification.

Figure 53 shows the carbon mapping of the fractured surfaces of 3D printed PDMS and
Dex-PDMS, with respective SEM images of fractured surfaces included for comparison.
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Similar to Figure 50, the SEM image of the naked PDMS cross-section (Figure 50A)
shows a smooth surface. The SEM image of the Dex-PDMS cross-section (Figure 50C)
shows physical conglomerations or particles, sitting within cavities. Analysis of the
carbon mapping images shows an even distribution of carbon in the PDMS cross-section
(Figure 50B). In the case of Dex-PDMS image, conglomerations are brighter meaning
that they contain higher amounts of carbon (Figure 50D). Dex has a higher carbon content
of 67% than PDMS, with a 32% carbon content. The higher carbon content in the
conglomerations suggests that they contain Dex (Figure 50). When the highlighted
particles are compared with the morphology images of the same surface, they align with
the micro particles within the cavities, which we can conclude are Dex. This image
provides evidence of the presence and even distribution of Dex throughout the printed
Dex-PDMS ink.

Figure 53. SEM images of fractured cross section of 3D printed PDMS inks (A) topographical SEM of
PDMS (B) Carbon analysis of PDMS (C) topographical SEM of Dex-PDMS (D) Carbon analysis of DexPDMS. Scale bar 10µm.
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4. Discussion
The results show that optimisation of the printing protocol enables 3D extrusion printing
of PDMS and Dex-PDMS inks under specific conditions. Whilst the PDMS ink does not
exhibit optimal printability, it can be seen that the print conditions can be optimised to
produce improved results. Properties such as a thermoset capability of the specific
Cochlear PDMS, can be taken advantage of in the 3D printing process. By 3D printing
thermoset inks onto a heated substrate, the spreading of the 3D printed struts can be
reduced. This is due to the improved cure kinetics dominating over any decrease in
viscosity, allowing them to maintain their shape fidelity and to become strong enough to
support successive layers, enabling 3D structure creation. This improved shape fidelity
enables the production of more precise and higher resolution 3D structures. A small
controlled amount of crosslinking could further improve printability. Further studies
would be required to carefully fine-tune the process to avoid nozzle clogging issues.
Printing PDMS inks becomes more difficult when trying to achieve very narrow struts
required for small 3D constructs but is achievable when this thermoset capability is
combined with the optimization of print speed, air pressure, needle size, and print speed.
The addition of drug to the ink also improves the achievability of high fidelity strut
production. Whilst the creation of struts with a circular cross section is often desired, is
not entirely necessary. 3D structure height can be achieved through design process with
the addition of layers catering for the actual shape of the struts produced. Small structure
production is limited by large strut widths. Narrow struts allow us to create narrow
structures suited for use in particular applications, such as within the narrow confines of
a cochlea. The fine layer heights allow us not only to create 3D structure with a finer
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resolution, but the large number of layers gives us the ability to manipulate the content of
more layers independently and therefore affect the functionality of those layers, especially
where it applies to drug delivery. In order to support these structures, the individual
PDMS struts need to strong enough to support successive layers.

Whilst successful over a short period of time, there are issues to be overcome in order to
use these print protocols going forward. Clogging of the nozzle during the printing
process became an issue during extended print times due to the heat rising from the
printing platform. As a result, increases in the temperature of the metal print tip, caused
curing of the PDMS and clogging. This part of the printing process could be improved
with the development of an effective heat shield or cooling mechanism around the tip to
keep it at room temperature. Printing onto Kapton tape enabled smooth printing and
makes the structures removable.

3D printed Dex-PDMS structures were shown to be capable of releasing dexamethasone
in a passive manner over a long period of time, making it a suitable base material for
sustained drug delivery. Given the capacity of the 3D printed construct to passively
release dexamethasone into an artificial perilymph solution, further investigation into the
ability to tailor the drug delivery profile is warranted. Modification of the design of the
structure by specifically locating drug loaded struts at specific points within the device
can impact where those drugs are delivered. This is especially critical in areas of the body
that are difficult to treat such as the small space within a cochlea. Modification to the
internal design of the device, which drives its porosity, can affect how much drug is
delivered and how quickly it is delivered. If initial burst release is indeed too intense, a
dampening of release controlled by the design is worthy of consideration. This could be
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achieved with an external layer of non-Dex loaded PDMS which could be tuned to a
thickness to specifically slow the surface release.

Further design options available within 3D printing, such as alternating layers of naked
and drug loaded PDMS, can affect the frequency of drug delivery. All of these things
have the potential to very specifically tailor drug delivery, by design, within a single
device.

In terms of applicability to cochlear implants, this research is still in its infancy. The
preferred external design of the electrode array must consider more than just shape and
size. The surface profile and texture of the resulting structure has the potential to impact
biological factors such as biofilm formation and protein adhesion and should be carefully
studied.

5. Future Directions
Further investigations into the specific impact to drug delivery profiles via the
manipulation of the printed structure in terms of layers could provide useful information
for future designs. Investigations into variable concentrations of drugs within the ink
should also be assessed for impact to printability, mechanical impact and drug release
profiles. In-depth studies are required to develop approaches for better control of drug
loading and release kinetics, to provide critical data set required to facilitate the
translation from bench to bedside. Additional tunability may be added to the design where
features such as delayed or reduced burst release of drugs is required. This could be
achieved with additional buffer layers of ink containing no drugs.
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Other 3D printing techniques could also provide valuable contributions in this area. Ink
jet printing provides the ability to print tiny droplets, which when assembled close
together can form a single layer. A very thin layer could be added, as an outer shell, to
the extrusion printed core without substantially increasing the overall size of the device.
By embedding this outer ink with higher concentration of drug or even an alternate drug,
more variation in release profiles could be achieved. A dual drug-eluting device could be
created to provide an initial burst of another drug, followed by the long-term release of a
second drug, or 2 different doses of the same drug with releases controlled by the coreshell construct of the device. Complex pulsed and bi-modal drug release profiles may be
achieved by combining layering and core-shell designs. There are many interesting
possibilities that could be explored.

3D printing has much to offer generically, as an alternative fabrication technique, to
industry, and also specifically, where there is currently exploration of embedded antiinflammatory drug delivery functionality within existing implants. The precision of
control, ability to work on a small scale, endless architectural possibilities and the
potential to fine tune and affect drug release profiles via clever designs has the potential
to produce more efficacious devices and improve clinical outcomes for patients.
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6. Ethical Considerations
Biofabrication is relatively new in the space of medical treatments. It is investigational in
its nature, and often used in a way that is unique to individual patients. Careful
consideration for patient care must be ethically examined. New treatments, such as
implantable drug delivery devices, require clinical trials, as for any new medical treatment
option. Where this device is embedded within another device, i.e. a cochlear implant, then
its impact on that device and the patient must both be considered within the trial. There
may be unanticipated consequences of modifying the manufacturing technique to include
3D printing, which should be clearly explained to the intended recipient. Ethical
principles such as autonomy and respect for trial participants are expected to be adhered
to. Researchers must pass on full knowledge and understanding of the potential benefits
and risks in a way that the participant can fully understand its implications, understand
how it applies to their situation, and make an informed choice on whether or not they wish
to participate.

The trial participants must be also permitted to change their mind which can be especially
difficult in the field of biofabrication where the trial involves an implantable device.
These devices need to be removable and this process must be considered as part of the
design of the trial. A participant may request removal at any time during their treatment
or indeed at any time over the lifetime of the device. A recipient with a hearing
impairment may choose to explant the hearing device that contains the 3D printed drug
delivery component – either because the device didn’t work as expected or perhaps due
to cultural sensitivities if they decide to adopt the Deaf culture. If this occurs, simply not
using the device may not be an option. As part of their identity, they may want the device
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removed and this must be made possible without serious side effects. This possibility of
explantation must be built into the design research from the earliest stages of the trials if
they are to receive ethical approval with regard to respect for the participants and patients.

To have merit, research must bring value to a field in order to satisfy the interests of the
researchers and the broader community. Whilst this research is not for the provision of a
new hearing solution, it aims to improve on the efficacy of a current solution. But more
than efficacy, the treatment must also be effective (Rogers, Degeling, & Townley, 2014)
if it is to satisfy the interests of recipients. Effectiveness includes soft goals such as quality
of life and overall health outcomes and depends not only on whether the treatment works
in ideal lab conditions, but also whether or not it works practically in the real world.
Effectiveness can have far wider implications for patients than immediate results obtained
in a perfect clinical setting. The research design should endeavor to address these goals
beyond the trial if it is to demonstrate an ethical concern for the long term merit of the
treatment and should do so in a transparent manner.

The ethical principle of beneficence, that is consideration for the welfare of others, should
be applied to the clinical trials required to move biofabricated implantable products to
market. The likely benefit of research for participants and future patients must be
considered to ensure their interests are maintained. This must be balanced with potential
risks, and the balance should lie on the side of benefit. With new and innovative materials
or processes such as those involved in biofabrication, these potential risks can be largely
unknown but are still required to be assessed for likelihood and severity. Once gauged,
management strategies should be developed to deal with these potential risks. One
management strategy is the gradual introduction of people to the trial over a period of
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time to limit the number of people exposed to risks until more is known. As safety is
proven on a few people, more participants could be invited to join the trial. The same
methodology could be applied in gradually introducing children to the trial where testing
is required so that they may eventually benefit from the treatment but not until safety is
proven on adult participants.

The risks to be considered must also take into account those that may occur beyond the
immediate life of the clinical trial and into the long term. These long-term risks may be
difficult to identify given there may be a limited number of similar treatments available
to compare them to, but tracking biofabricated components for their lifetime and
monitoring the welfare of the recipients should be considered.

While biofabrication is evolving, oversight must be maintained to ensure patient welfare
is maintained and that participant welfare is not harmed in the process. The interests of
research participants and future patients are required to be balanced and this oversight
should be maintained by regulation and ethical review. Because biofabrication is an
emerging technology, there is an increased chance that there may be many unknown
potential risks both immediately and, in the future, and thus caution is required.
Independent advisors, gradual exposure of limited participants to clinical trials, early
engagement of the community, full analysis of risks and benefits, effectiveness studies,
consideration to the long-term, and transparency across all clinical trials are just some of
the ways in which these issues can be ethically managed.
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8. Appendix I: Strut Dimension Calculations
X = horizontal distance from 0

Z = Vertical Distance from 0

XnZn = Data Point Pair

Slopen = (Zn –Z(n-1)) / (X(n)-X(n-1))

If Slope(n-1) <= 0 AND Slopen > 0
then
Strut(START) = (XnZn)

If Slope(n-1) < 0 AND Slopen >= 0
then
Strut(END) = (XnZn)

If Slope(n) > 0 AND Slope(n+1) <= 0
then
Strut(PEAK) = (XnZn)

Strut Width = Strut(END) – Strut(START)
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